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Summary
Background Comprehensive and comparable estimates of health spending in each country are a key input for health 
policy and planning, and are necessary to support the achievement of national and international health goals. Previous 
studies have tracked past and projected future health spending until 2040 and shown that, with economic development, 
countries tend to spend more on health per capita, with a decreasing share of spending from development assistance 
and out-of-pocket sources. We aimed to characterise the past, present, and predicted future of global health spending, 
with an emphasis on equity in spending across countries.
Methods We estimated domestic health spending for 195 countries and territories from 1995 to 2016, split into three 
categories—government, out-of-pocket, and prepaid private health spending—and estimated development assistance 
for health (DAH) from 1990 to 2018. We estimated future scenarios of health spending using an ensemble of linear 
mixed-effects models with time series specifications to project domestic health spending from 2017 through 2050 
and DAH from 2019 through 2050. Data were extracted from a broad set of sources tracking health spending and 
revenue, and were standardised and converted to inflation-adjusted 2018 US dollars. Incomplete or low-quality data 
were modelled and uncertainty was estimated, leading to a complete data series of total, government, prepaid private, 
and out-of-pocket health spending, and DAH. Estimates are reported in 2018 US dollars, 2018 purchasing-power 
parity-adjusted dollars, and as a percentage of gross domestic product. We used demographic decomposition 
methods to assess a set of factors associated with changes in government health spending between 1995 and 2016 
and to examine evidence to support the theory of the health financing transition. We projected two alternative future 
scenarios based on higher government health spending to assess the potential ability of governments to generate 
more resources for health.
Findings Between 1995 and 2016, health spending grew at a rate of 4·00% (95% uncertainty interval 3·89–4·12) 
annually, although it grew slower in per capita terms (2·72% [2·61–2·84]) and increased by less than $1 per capita 
over this period in 22 of 195 countries. The highest annual growth rates in per capita health spending were observed 
in upper-middle-income countries (5·55% [5·18–5·95]), mainly due to growth in government health spending, and 
in lower-middle-income countries (3·71% [3·10–4·34]), mainly from DAH. Health spending globally reached 
$8·0 trillion (7·8–8·1) in 2016 (comprising 8·6% [8·4–8·7] of the global economy and $10·3 trillion [10·1–10·6] in 
purchasing-power parity-adjusted dollars), with a per capita spending of US$5252 (5184–5319) in high-income 
countries, $491 (461–524) in upper-middle-income countries, $81 (74–89) in lower-middle-income countries, and 
$40 (38–43) in low-income countries. In 2016, 0·4% (0·3–0·4) of health spending globally was in low-income 
countries, despite these countries comprising 10·0% of the global population. In 2018, the largest proportion of 
DAH targeted HIV/AIDS ($9·5 billion, 24·3% of total DAH), although spending on other infectious diseases 
(excluding tuberculosis and malaria) grew fastest from 2010 to 2018 (6·27% per year). The leading sources of DAH 
were the USA and private philanthropy (excluding corporate donations and the Bill & Melinda Gates Foundation). 
For the first time, we included estimates of China’s contribution to DAH ($644·7 million in 2018). Globally, health 
spending is projected to increase to $15·0 trillion (14·0–16·0) by 2050 (reaching 9·4% [7·6–11·3] of the global 
economy and $21·3 trillion [19·8–23·1] in purchasing-power parity-adjusted dollars), but at a lower growth rate of 
1·84% (1·68–2·02) annually, and with continuing disparities in spending between countries. In 2050, we estimate 
that 0·6% (0·6–0·7) of health spending will occur in currently low-income countries, despite these countries 
comprising an estimated 15·7% of the global population by 2050. The ratio between per capita health spending in 
high-income and low-income countries was 130·2 (122·9–136·9) in 2016 and is projected to remain at similar levels 
in 2050 (125·9 [113·7–138·1]). The decomposition analysis identified governments’ increased prioritisation of the 
health sector and economic development as the strongest factors associated with increases in government health 
spending globally. Future government health spending scenarios suggest that, with greater prioritisation of the 
health sector and increased government spending, health spending per capita could more than double, with greater 
impacts in countries that currently have the lowest levels of government health spending.
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Interpretation Financing for global health has increased steadily over the past two decades and is projected to continue 
increasing in the future, although at a slower pace of growth and with persistent disparities in per-capita health 
spending between countries. Out-of-pocket spending is projected to remain substantial outside of high-income 
countries. Many low-income countries are expected to remain dependent on development assistance, although with 
greater government spending, larger investments in health are feasible. In the absence of sustained new investments 
in health, increasing efficiency in health spending is essential to meet global health targets.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Financial resources are an essential input to health 
systems—at a minimum, these are necessary to purchase 
medicines and supplies, build health facilities, and pay 
health workers. However, limited financial resources are 
a universal constraint faced by all health systems. WHO 
has identified health financing as one of the six key 
building blocks of health systems and adequate financing 
is essential to the other five blocks.1 Health financing 
systems are tasked not only with raising sufficient financial 
resources to fund the health system, but doing so in a way 
that promotes equity.2 Health systems funded according to 
one’s ability to pay, such as those based on income taxes, 
promote both financial equity and better health.3 Over-
reliance on out-of-pocket spending diminishes access to 
care for those who are uninsured or underinsured, and 
risks exacerbating the burden of ill health and increasing 
poverty due to the high cost of care.4 The recognised 
importance of financial protection has led to its inclusion 
as one of two pillars of universal health coverage, alongside 
coverage of core health services, as outlined in Sustainable 
Development Goal 3.
Research in context
Evidence before this study
Understanding past trends and anticipating future trends in 
health financing is important for planning and allocating 
resources required to achieve universal health coverage and 
other health goals. Previous studies, including work by the Global 
Burden of Disease Health Financing Collaborator Network, 
have tracked past and projected future health spending and 
spending disaggregated by funding source (ie, government, 
prepaid private, out-of-pocket, and development assistance for 
health) up to 2040. A 2018 report from WHO documents the 
global pattern of declining external financing and increasing 
domestic public funding, supporting key findings from other 
existing studies. Research focusing on the global health financing 
transition by this team and others has shown that with economic 
development, countries tend to spend more money on health 
per capita and that a declining share of this spending tends to 
come from development assistance and out-of-pocket sources.
Added value of this study
This study is, to our knowledge, the first analysis of global health 
financing to generate past trends, characterise present patterns, 
and predict future scenarios for 195 countries over a period 
spanning 56 years, with an emphasis on equity across countries 
over time, providing a holistic assessment of the state of global 
health financing. This analysis provides new estimates of total, 
government, prepaid private, and out-of-pocket health spending 
and development assistance for health for 195 countries 
spanning from 1995 to 2050. The relationship between 
economic development and the distribution of these sources of 
financing provides further support for the theory of the global 
health financing transition. The decomposition analysis shows, 
for the first time, key factors that have been associated with 
increases in government health spending across countries, 
showing that increased prioritisation of the health sector and 
economic development are associated with the largest increases 
in government health spending globally. These time trends in 
health spending also reveal persistent disparities across income 
groups, with per capita health spending in high-income 
countries 130·2 times (95% uncertainty interval 122·9–136·9) 
that in low-income countries in 2016, and projected to remain 
stable at 125·9 times (113·7–138·1) greater in 2050. Within 
low-income and middle-income country groups, the gaps 
between countries with the highest and lowest government 
health spending per capita are projected to widen between 
now and the future. Furthermore, consistently high rates of 
out-of-pocket spending in low-income and middle-income 
countries suggest ongoing within-country inequities. Although 
these trends also provide evidence of the global health financing 
transition, many countries’ trends run counter to global norms.
Implications of all the available evidence
Development assistance for health has plateaued; moreover, 
projected future spending suggests that low levels of domestic 
health spending and high out-of-pocket spending will persist in 
many low-income countries. Increasing prioritisation of health 
and economic development should be supported as key 
mechanisms to increase government health spending and 
address persistent global inequities in health spending. 
Given the limited financial resources for health in all countries 
and persistently low levels of health financing in some, it is 
important to identify and implement policies to generate 
additional resources and improve the efficiency of health 
spending to maximise health outcomes in the future.
For more on Sustainable 
Development Goal 3 see 
https://www.who.int/sdg/
targets/en/
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Empirical studies have shown that reducing government 
health spending per capita can lead to increased child, 
adult, and maternal mortality.5–8 Other research has 
found that countries with lower levels of health spending 
coming from pooled financing mechanisms, such as 
insurance-based or tax-based financing, have lower 
performance on universal health coverage.9 These 
benefits and the established risks of high out-of-pocket 
spending have led to a focus on the composition of 
sources of health financing across countries. The health 
financing transition is a theory developed to characterise 
the gradual shift in the level and source of health 
financing observed in countries over time. Generally, 
countries start this transition with a low initial level of 
health spending per capita that is largely out of pocket or 
from donors, and progressively transition to higher per 
capita spending relying more on government financing.
Tracking financial resources for health is a prerequis ite for 
assessing the performance of health financing systems 
and financial protection, characterising progress along 
the health financing transition, evaluating health-system 
efficiency and productivity, or advocating for health-
system policy change. Moreover, developing future 
health financing scenarios enables policy makers and 
donors to predict the amount of services that can be 
provided and identify gaps where expected funding is 
insufficient. Established frameworks and examples from 
a range of countries underscore the important role of 
timely, comprehensive health financing estimates in 
decision making and analysis.10,11 As countries work 
towards global commitments to universal health coverage 
and the other health-related targets enshrined in the UN 
Sustainable Development Goals, the expected resources 
available for health can be used to assess expected 
progress. In the absence of comprehensive and 
comparable health financing estimates, policy makers 
and planners cannot clearly measure how much has 
been spent on health, where funding has come from, or 
what are reasonable expectations for future spending.
This study incorporates several important methodo-
logical advancements and novel analyses. The health 
financing estimation methods are continuously im-
proving and forecasting is particularly enhanced by 
advances in the underlying approach to project gross 
domestic product (GDP). The time horizon for spending 
forecasts is 10 years longer than previously available 
and alternative future scenarios are based, for the first 
time, on a new understanding of factors associated 
with increased government spending, as identified from 
the decomposition analysis, also new to this study. 
Additionally, these estimates include seven additional 
countries or territories not previously included. There 
are also several advances specific to the development 
assistance for health (DAH) estimates, including the 
addition of China as a donor, inclusion of the Coalition for 
Epidemic Preparedness Innovations and the European 
Economic Area as channels of disbursements, and 
spending disaggregated by new programme areas, such 
as antimicrobial resistance.
The objective of this analysis is to provide comprehensive 
and comparable national health spending estimates, by 
four major sources of funding, from 1995 to 2016 and into 
2050, emphasising equity in spending across countries 
over time. We also characterise health spending patterns 
associated with economic development to assess support 
for the theory of the health financing transition, analyse 
factors associated with increases in government health 
spending, and report expected future spending under 
two alternative government spending scenarios. 
Methods
Overview
The methods presented here summarise the various 
components of the estimation process; the appendix 
provides further details about data sources, methods, and 
additional results presented in alternative units. We 
defined health spending as money spent on services, 
supplies, and basic infrastructure to deliver health care, 
using the same definition used by the System of Health 
Accounts 2011 and the WHO Global Health Expenditure 
Database (GHED).12,13
We estimated health spending from four main 
funding sources—government, out-of-pocket, prepaid 
private, and DAH—for 195 countries and territories. 
“Countries and territories” are referred to only as 
“countries”, which are categorised into four World Bank 
income groups and seven Global Burden of Disease 
(GBD) super-regions. Data tracking government, out-
of-pocket, and prepaid private health spending, which 
together comprise total domestic health spending, were 
available from 1995 through 2016. Government health 
spending includes social health insurance and man-
dated private health insurance, as well as government 
public health programmes. Out-of-pocket health 
spending includes health-care spending by the patient 
or their household, excluding insurance premiums 
paid in advance of care. Prepaid private health spending 
includes voluntary private insurance and non-govern-
mental agency spending on health.
DAH was defined as the financial and in-kind 
contributions from major development agencies to low-
income and middle-income countries for maintaining or 
improving population health. The total amount of DAH, 
by source, was estimated through 2018, but was not 
allocated by recipient country for 2018. The sum of 
domestic health spending and DAH, net of administrative 
costs needed to run development agencies, form the 
envelope of total health spending for each country and 
year.
Domestic health spending from each of the three sources 
was projected for each country from 2017 to 2050, and 
DAH was projected from 2018 to 2050, by modelling 
rates of change across time. These models incorporate 
country-specific time trends that attenuate across time 
See Online for appendix
For more on the UN Sustainable 
Development Goals see 
https://www.un.org/
sustainabledevelopment/
sustainable-development-goals/
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and converge to the global average, consider a broad set 
of covariates and time-series modelling techniques, 
and propagate four types of uncertainty: model, data, 
parameter, and fundamental uncertainty.
Estimating domestic health spending for 1995–2016
We extracted data on GDP per capita from five leading 
sources of these estimates.14–18 Building from methods 
described by James and colleagues,19 we generated a 
single series of GDP per capita using Gaussian processes, 
incorporating data from all five GDP series from 
1970 to 2017.19
We extracted data from the WHO’s GHED on 
government domestic revenue transfers allocated for 
health, compulsory prepayment, voluntary prepayment, 
social insurance contributions, and other domestic 
revenue from households, corporations, and non-profit 
institutions serving households.12 Data from GHED 
exclude spending on major investments (eg, hospital 
construction, health worker education and training, and 
research and development). Health spending estimates 
were extracted in current national currency units, 
deflated to 2018 national currency units, and exchanged 
to 2018 US dollars. Deflator series and exchanges rates 
were taken from the IMF World Economic Outlook.16 
To generate domestic health spending estimates in 
purchasing-power parity-adjusted dollars, we divided 
health spending in 2018 US dollars by GDP in 2018 US 
dollars, and then multiplied health spending fractions 
by GDP per capita measured in 2018 purchasing-power 
parity-adjusted dollars.
The extracted data were assessed for quality using 
point-specific metadata provided in the GHED, and 
weighted according to estimation methods and whether 
they were tied to an underlying data source. We then 
used a spatiotemporal Gaussian process regression 
model to estimate health spending across time, country, 
and spending category.20 We based weights on metadata 
completeness, documented source information, and 
documented methods for estimation.
Estimating development assistance for health for 
1990–2018
Although most of the methods used for tracking DAH 
have been described previously, we incorporated several 
major improvements.21–25 These include the addition of 
China as a source of funding; the inclusion of the 
Coalition for Epidemic Preparedness Innovations as a 
channel; and the addition of antimicrobial resistance as 
a programme area. The estimate we generated for 
antimicrobial resistance is restricted to funds that 
were disbursed through development agencies. These 
improvements expand the scope of our DAH resource 
tracking to capture some of the emerging areas of 
importance in the current global health financing 
landscape. For all DAH tracking, we include funds that 
were transferred through major development agencies, 
as well as private foundations and non-governmental 
agencies for whom we have data. DAH excludes 
spending on basic bench science. Detailed descriptions 
of the methodology used for tracking DAH and these 
improve ments, including data sources and keywords 
used to isolate relevant projects, are included in the 
appendix.
Factors associated with changes in government health 
spending for 1995–2016
We completed a decomposition analysis to understand 
the relationship between changes in per capita govern-
ment health spending between 1995 and 2016 and the 
underlying contributing factors. A standard demographic 
decomposition technique popularised by Das Gupta was 
applied; this approach yields estimates of how changes in 
each of a set of prespecified factors are associated with 
changes in the outcome (government health spending per 
capita).26 The three factors examined were economic 
development, measured as GDP per person (GDP/Pop); 
increased total government spending, measured as 
the proportion of GDP that is government spending 
(Gov/GDP); and greater government prioritisation of 
the health sector, measured as the proportion of total 
government spending spent on the health sector 
(Gov Health/Gov). The product of these three factors is 
government health spending per capita (Gov Health/Pop):
These three factors form a comprehensive set, as all 
other factors that influence government health spending 
must operate through one or more of those factors. For 
example, if demand for health services increases or a 
population ages and requires additional health services 
from the government, this must lead to an increase in total 
government spending or a reprioritisation of existing 
government spending towards health. This decomposition 
approach measures the relative contribution of each factor 
to changes in per capita government health spending 
during the time period examined.
Estimating health spending in the future, for 2017–50
Future health spending scenarios were estimated with an 
ensemble modelling framework and key covariates. A 
process diagram in the appendix displays the flow of 
input data and models for each step of the forecasting 
process. Ensemble modelling estimates a set of future 
scenarios using a large number of distinct sub-models 
and then takes the average across all sub-models that 
pass a predetermined inclusion criterion.27 Each sub-
model has a distinct specification or set of covariates; 
primary covariates considered were GDP per capita, total 
government spending, total fertility rate, and fraction of 
the population older than 65 years, as well as country-
specific time trends. Total fertility rates and age-specific 
=Gov Health
Pop
GDP
Pop
Gov 
GDP
Gov Health
Gov
× ×
Articles
www.thelancet.com   Vol 393   June 1, 2019 2237
A
B
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
1995
2016
5 to <118
118 to <389
389 to <892
892 to <2406
2406 to <15 826
Health spending per capita (US$)
5 to <118
118 to <389
389 to <892
892 to <2406
2406 to <15 826
Health spending per capita (US$)
(Figure 1 continues on next page)
Articles
2238 www.thelancet.com   Vol 393   June 1, 2019
C
D
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
2030
2050
5 to <118
118 to <389
389 to <892
892 to <2406
2406 to <15 826
Health spending per capita (US$)
5 to <118
118 to <389
389 to <892
892 to <2406
2406 to <15 826
Health spending per capita (US$)
Articles
www.thelancet.com   Vol 393   June 1, 2019 2239
population data were extracted from the UN World 
Population Prospects, while we generated our own 
estimates of GDP per capita and fraction of GDP from 
government spending.28
To project expected GDP per capita for each of the 
195 countries from 2018 through 2050, we estimated 
the GDP per working-age adult growth rate (ages 
20–64 years). Using out-of-sample validation, we showed 
that GDP per capita could be more accurately estimated 
(smaller root-mean-squared error) by estimating GDP 
per working-age adult growth rates, rather than GDP per 
capita growth rates.
After estimating GDP per capita, we used the same 
method to estimate future scenarios of total government 
spending as a fraction of GDP, government health 
spending as a fraction of total government spending, 
prepaid private health spending as a fraction of GDP, 
and out-of-pocket health spending as a fraction of 
GDP. We called these our reference future scenarios. 
Additionally, we estimated future scenarios of the share 
of health spending that was provided as DAH from each 
major donor country, which allowed us to estimate total 
DAH expected to be disbursed between 2019 and 2050. 
Next, we estimated the fraction of the total amount of 
DAH that we expected each low-income and middle-
income country to receive. Finally, if a country was 
projected to reach high-income status before 2050, it was 
deemed ineligible to receive DAH from that year onward 
and the DAH it was otherwise expected to receive was 
reallocated to all other countries eligible to receive DAH. 
To estimate total health spending for each country and 
year, we added DAH received by countries to estimates 
of government, prepaid private, and out-of-pocket health 
spending.
Alternative future government health spending 
scenarios
To assess the potential for governments to generate 
more resources for health, we estimated two alternative 
future scenarios associated with higher government 
health spending: one reflects increased prioritisation of 
the health sector, and the other reflects both increased 
overall government spending and increased government 
prioritisation of health. To generate the two scenarios, 
we assessed the observed 2016 fraction of government 
spending that was allocated to the health sector 
(Gov Health/Gov) and the fraction of GDP that is 
based on government spending (Gov/GDP) across the 
195 countries. We then set the target levels of the 
two fractions as the 90th percentile of the observed 
fractions’ distributions. Building on the existing GDP 
per capita projections, scenario 1 adjusts all countries so 
that the fraction of government spending on health is at 
least the 90th percentile. Scenario 2 adjusts all countries 
so that both the fraction of government spending on 
health and the fraction of GDP that is based on 
government spending is at least the 90th percentile.
Reporting and uncertainty analysis
All inflation-adjusted health spending estimates are 
reported with 2018 prices. We report health spending 
per capita in US dollars and purchasing-power parity-
adjusted dollars and as a fraction of GDP. When not 
other wise indicated, estimates are reported in 2018 
US dollars. We report country spending estimates using 
2017 GBD super-regions and 2018 World Bank income 
groups, regardless of whether a country changed, or is 
projected to change, income groups during the study 
period.29,30 Rates were calculated to reflect each group, 
rather than the average of countries within the group, 
such that spending per capita estimates for an income 
group or region more heavily reflect rates in more 
populous countries. The uncertainty interval around 
each estimate was computed with the 2·5th and 
97·5th percentiles of the 1000 draws. All analyses were 
done with R (version 3.5.2) and Stata (version 13).
Role of the funding source
The funder of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the manuscript. All authors had full access to 
all the data in the study, and JLD and CJLM had 
final responsibility for the decision to submit for 
publication.
Figure 1: Health spending per capita in 1995 (A), 2016 (B), 2030 (C), 
and 2050 (D)
Reported in inflation-adjusted 2018 US dollars. 2030 and 2050 values are 
reference scenarios. This figure was remade but with health spending measured 
as a percentage of gross domestic product, and is included in the appendix. 
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. 
LCA=Saint Lucia. TTO=Trinidad and Tobago. Isl=Islands. FSM=Federated States 
of Micronesia. TLS=Timor-Leste.
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Figure 2: Health spending per capita by gross domestic product per capita, for 1995, 2016, 2030, and 2050
Health spending per capita and gross domestic product per capita are reported in inflation-adjusted 2018 US dollars. 
The lines are the trend lines reflecting model fit for each year. 2030 and 2050 values are reference scenarios. Each dot 
represents a country-year estimate, with the colours representing different years (1995, 2016, 2030, and 2050). 
The x-axis is presented in natural logarithmic scale. This figure was remade but with health spending measured as a 
percentage of gross domestic product, and is included in the appendix.
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Annualised rate 
of change in 
health spending 
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1995–2016 
(US$)
Global
Total 1077 
(1058 to 1096)
1400 
(1368 to 1432)
8·6% 
(8·4 to 8·7)
74·0% 
(72·5 to 75·5)
18·6% 
(18·0 to 19·4)
0·2% 
(0·2 to 0·2)
4·00% 
(3·89 to 4·12)
2·72% 
(2·61 to 2·84)
1·02% 
(0·92 to 1·12)
World Bank income group
High income 5252 
(5184 to 5319)
5621 
(5548 to 5693)
10·8% 
(10·6 to 10·9)
79·6% 
(78·2 to 81·1)
13·8% 
(13·5 to 14·2)
0·0% 
(0·0 to 0·0)
3·61% 
(3·51 to 3·71)
2·92% 
(2·81 to 3·02)
1·52% 
(1·42 to 1·62)
Upper-middle 
income
491 
(461 to 524)
1009 
(948 to 1072)
5·0% 
(4·7 to 5·3)
53·9% 
(49·9 to 58·6)
35·9% 
(32·0 to 40·0)
0·2% 
(0·1 to 0·2)
6·37% 
(5·95 to 6·79)
5·55% 
(5·18 to 5·95)
1·17% 
(0·81 to 1·55)
Lower-middle 
income
81 
(74 to 89)
274 
(247 to 303)
3·2% 
(2·9 to 3·5)
32·1% 
(28·4 to 36·1)
56·1% 
(47·3 to 65·4)
3·2% 
(2·9 to 3·6)
5·40% 
(4·76 to 6·08)
3·71% 
(3·10 to 4·34)
0·00% 
(–0·63 to 0·60)
Low income 40 
(38 to 43)
125 
(119 to 132)
5·1% 
(4·9 to 5·4)
26·3% 
(23·3 to 29·5)
42·4% 
(38·3 to 47·0)
25·4% 
(23·9 to 26·8)
4·25% 
(3·88 to 4·62)
1·46% 
(1·13 to 1·80)
0·39% 
(0·05 to 0·70)
GBD super-region
Central Europe, 
eastern Europe, 
and central Asia
530 
(505 to 555)
1265 
(1200 to 1330)
4·3% 
(4·1 to 4·5)
62·6% 
(59·4 to 65·9)
33·5% 
(31·3 to 35·8)
0·3% 
(0·2 to 0·3)
3·44% 
(3·10 to 3·81)
3·41% 
(3·06 to 3·77)
0·06% 
(–0·26 to 0·37)
High income 5874 
(5798 to 5950)
6107 
(6028 to 6185)
11·2% 
(11·1 to 11·4)
79·9% 
(78·5 to 81·5)
13·5% 
(13·2 to 13·9)
0·0% 
(0·0 to 0·0)
3·57% 
(3·47 to 3·68)
2·93% 
(2·82 to 3·03)
1·59% 
(1·49 to 1·69)
Latin America and 
Caribbean
693 
(658 to 728)
1270 
(1209 to 1333)
6·4% 
(6·1 to 6·7)
42·7% 
(40·3 to 44·9)
39·5% 
(36·0 to 43·2)
0·3% 
(0·3 to 0·3)
4·21% 
(3·83 to 4·62)
2·84% 
(2·48 to 3·22)
1·56% 
(1·20 to 1·93)
North Africa and 
Middle East
336 
(320 to 352)
1000 
(949 to 1053)
3·7% 
(3·5 to 3·9)
61·4% 
(56·9 to 65·9)
29·3% 
(27·5 to 31·3)
0·5% 
(0·4 to 0·5)
6·01% 
(5·66 to 6·42)
3·92% 
(3·60 to 4·25)
1·87% 
(1·58 to 2·19)
South Asia 59 
(49 to 71)
219 
(182 to 265)
3·0% 
(2·5 to 3·5)
25·0% 
(18·7 to 32·2)
65·2% 
(46·7 to 88·1)
1·9% 
(1·6 to 2·3)
5·76% 
(4·42 to 7·15)
4·09% 
(2·81 to 5·44)
–0·73% 
(–1·96 to 0·59)
Southeast Asia, 
east Asia, and 
Oceania
350 
(319 to 385)
703 
(643 to 769)
4·7% 
(4·3 to 5·1)
57·5% 
(50·8 to 65·5)
35·9% 
(30·0 to 42·8)
0·2% 
(0·2 to 0·2)
9·35% 
(8·56 to 10·14)
8·52% 
(7·69 to 9·33)
1·72% 
(0·98 to 2·45)
Sub-Saharan Africa 80 
(75 to 86)
199 
(186 to 214)
4·1% 
(3·9 to 4·3)
36·8% 
(34·0 to 39·8)
31·5% 
(27·3 to 36·3)
14·0% 
(13·1 to 14·9)
4·31% 
(3·88 to 4·76)
1·54% 
(1·08 to 1·97)
–0·17% 
(–0·58 to 0·21)
Country
Afghanistan 56 
(43 to 71)
200 
(156 to 256)
7·4% 
(5·8 to 9·5)
5·7% 
(3·9 to 7·9)
84·3% 
(80·0 to 88·0)
9·7% 
(7·5 to 12·3)
7·06% 
(5·15 to 9·12)
3·41% 
(1·57 to 5·40)
1·07% 
(–0·73 to 3·01)
Albania 330 
(292 to 371)
867 
(768 to 976)
6·0% 
(5·3 to 6·7)
42·3% 
(36·5 to 48·1)
57·2% 
(51·3 to 63·0)
0·5% 
(0·4 to 0·6)
4·31% 
(3·28 to 5·26)
4·74% 
(3·70 to 5·68)
–0·04% 
(–1·04 to 0·86)
Algeria 304 
(267 to 341)
1055 
(926 to 1184)
4·7% 
(4·1 to 5·2)
69·4% 
(63·4 to 74·8)
29·2% 
(23·8 to 34·8)
0·0% 
(0·0 to 0·0)
6·71% 
(5·72 to 7·69)
5·12% 
(4·14 to 6·09)
3·18% 
(2·22 to 4·13)
American Samoa 692 
(604 to 791)
692 
(604 to 791)
6·4% 
(5·6 to 7·4)
90·1% 
(86·5 to 93·0)
8·3% 
(5·8 to 11·7)
0·0% 
(0·0 to 0·0)
–0·20% 
(–1·55 to 1·01)
–2·20% 
(–3·52 to –1·01)
–1·65% 
(–2·97 to –0·45)
Andorra 4234 
(4107 to 4357)
7865 
(7629 to 8093)
8·2% 
(7·9 to 8·4)
48·9% 
(47·5 to 50·3)
41·9% 
(40·5 to 43·2)
0·0% 
(0·0 to 0·0)
2·50% 
(2·27 to 2·73)
1·13% 
(0·91 to 1·36)
–0·07% 
(–0·29 to 0·15)
Angola 121 
(100 to 143)
201 
(167 to 237)
2·4% 
(2·0 to 2·8)
48·3% 
(39·7 to 56·7)
31·7% 
(24·3 to 40·2)
3·6% 
(3·0 to 4·3)
3·24% 
(1·98 to 4·43)
–0·12% 
(–1·34 to 1·04)
–3·81% 
(–4·98 to –2·69)
Antigua and Barbuda 760 
(712 to 811)
1233 
(1156 to 1316)
4·8% 
(4·5 to 5·2)
64·4% 
(61·3 to 67·7)
29·1% 
(26·2 to 32·2)
0·0% 
(0·0 to 0·0)
3·98% 
(3·44 to 4·57)
2·48% 
(1·94 to 3·06)
1·28% 
(0·75 to 1·86)
Argentina 1071 
(1008 to 1135)
1616 
(1520 to 1713)
7·9% 
(7·5 to 8·4)
76·1% 
(73·5 to 78·9)
14·8% 
(12·7 to 16·9)
0·7% 
(0·6 to 0·7)
1·83% 
(1·39 to 2·25)
0·68% 
(0·24 to 1·09)
–0·69% 
(–1·13 to –0·29)
Armenia 365 
(323 to 411)
933 
(827 to 1051)
7·8% 
(6·9 to 8·8)
15·8% 
(12·5 to 19·7)
81·1% 
(77·0 to 84·5)
1·9% 
(1·7 to 2·2)
10·73% 
(9·69 to 11·80)
11·04% 
(10·01 to 12·12)
4·25% 
(3·28 to 5·27)
Australia 5563 
(5476 to 5650)
5083 
(5004 to 5162)
7·1% 
(7·0 to 7·2)
68·3% 
(67·4 to 69·3)
18·9% 
(18·1 to 19·6)
0·0% 
(0·0 to 0·0)
4·72% 
(4·56 to 4·89)
3·28% 
(3·12 to 3·44)
1·47% 
(1·31 to 1·63)
Austria 5287 
(5199 to 5379)
5252 
(5166 to 5344)
9·2% 
(9·0 to 9·3)
72·6% 
(71·7 to 73·4)
18·9% 
(18·3 to 19·6)
0·0% 
(0·0 to 0·0)
2·20% 
(2·05 to 2·35)
1·76% 
(1·61 to 1·91)
0·43% 
(0·28 to 0·58)
Azerbaijan 297 
(261 to 335)
1192 
(1048 to 1347)
3·6% 
(3·2 to 4·1)
20·6% 
(16·5 to 25·2)
78·3% 
(73·6 to 82·5)
0·3% 
(0·3 to 0·4)
10·29% 
(9·06 to 11·44)
9·00% 
(7·79 to 10·14)
1·27% 
(0·14 to 2·33)
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Bahrain 1169 
(1109 to 1233)
2365 
(2243 to 2494)
4·3% 
(4·0 to 4·5)
62·7% 
(59·9 to 65·4)
27·1% 
(24·8 to 29·6)
0·0% 
(0·0 to 0·0)
5·39% 
(4·91 to 5·85)
1·00% 
(0·55 to 1·44)
0·88% 
(0·42 to 1·32)
Bangladesh 37 
(29 to 48)
100 
(78 to 128)
3·1% 
(2·4 to 3·9)
19·2% 
(13·7 to 26·0)
71·4% 
(62·8 to 78·6)
6·7% 
(5·1 to 8·4)
5·42% 
(3·78 to 7·11)
3·81% 
(2·19 to 5·47)
–0·41% 
(–1·96 to 1·19)
Barbados 1188 
(1124 to 1257)
1244 
(1177 to 1316)
6·3% 
(6·0 to 6·7)
46·9% 
(44·1 to 49·6)
45·8% 
(43·0 to 48·2)
0·0% 
(0·0 to 0·0)
2·21% 
(1·73 to 2·65)
1·86% 
(1·38 to 2·30)
0·81% 
(0·33 to 1·24)
Belarus 354 
(318 to 396)
1170 
(1051 to 1308)
5·0% 
(4·5 to 5·5)
61·1% 
(55·1 to 66·6)
35·9% 
(30·5 to 41·9)
0·3% 
(0·3 to 0·3)
5·60% 
(4·67 to 6·57)
5·93% 
(4·99 to 6·89)
0·44% 
(–0·45 to 1·35)
Belgium 5014 
(4894 to 5135)
5048 
(4927 to 5169)
9·2% 
(8·9 to 9·4)
79·1% 
(78·1 to 80·0)
15·1% 
(14·4 to 16·0)
0·0% 
(0·0 to 0·0)
3·18% 
(2·96 to 3·39)
2·61% 
(2·40 to 2·82)
1·36% 
(1·15 to 1·57)
Belize 283 
(249 to 317)
511 
(449 to 573)
5·6% 
(4·9 to 6·3)
66·3% 
(60·1 to 72·0)
23·4% 
(18·4 to 29·0)
3·5% 
(3·1 to 3·9)
6·29% 
(5·27 to 7·28)
3·37% 
(2·38 to 4·33)
2·16% 
(1·18 to 3·11)
Benin 32 
(27 to 38)
83 
(70 to 98)
3·1% 
(2·6 to 3·6)
22·3% 
(16·7 to 28·1)
44·3% 
(35·3 to 53·4)
27·5% 
(23·0 to 32·3)
3·76% 
(2·46 to 5·04)
0·56% 
(–0·70 to 1·81)
–0·83% 
(–2·07 to 0·40)
Bermuda 10 802 
(9469 to 12 352)
6982 
(6120 to 7983)
11·5% 
(10·1 to 13·2)
29·1% 
(25·1 to 33·0)
10·2% 
(7·7 to 13·4)
0·0% 
(0·0 to 0·0)
3·05% 
(1·35 to 4·55)
1·93% 
(0·25 to 3·41)
0·87% 
(–0·80 to 2·33)
Bhutan 84 
(69 to 100)
258 
(213 to 306)
2·5% 
(2·1 to 3·0)
72·7% 
(65·4 to 78·9)
20·0% 
(14·5 to 27·3)
6·1% 
(5·1 to 7·3)
4·75% 
(3·41 to 6·13)
2·62% 
(1·31 to 3·97)
–2·38% 
(–3·63 to –1·10)
Bolivia 214 
(185 to 246)
486 
(420 to 558)
6·7% 
(5·8 to 7·7)
66·7% 
(59·7 to 73·1)
28·1% 
(21·7 to 35·3)
1·8% 
(1·6 to 2·1)
6·83% 
(5·69 to 7·94)
4·94% 
(3·83 to 6·04)
2·52% 
(1·43 to 3·59)
Bosnia and 
Herzegovina
517 
(473 to 569)
1251 
(1144 to 1376)
8·0% 
(7·3 to 8·7)
68·5% 
(64·1 to 72·6)
27·6% 
(23·6 to 32·0)
2·0% 
(1·8 to 2·2)
8·31% 
(7·40 to 9·21)
8·48% 
(7·57 to 9·39)
0·42% 
(–0·43 to 1·25)
Botswana 427 
(380 to 478)
1000 
(890 to 1119)
4·4% 
(3·9 to 4·9)
54·5% 
(48·7 to 60·2)
5·3% 
(3·8 to 7·2)
8·4% 
(7·5 to 9·4)
3·73% 
(2·97 to 4·55)
1·82% 
(1·07 to 2·63)
–0·99% 
(–1·71 to –0·20)
Brazil 1114 
(1040 to 1195)
1864 
(1739 to 2000)
8·0% 
(7·5 to 8·6)
33·3% 
(30·1 to 36·2)
43·9% 
(40·5 to 47·5)
0·1% 
(0·1 to 0·1)
4·58% 
(4·03 to 5·21)
3·35% 
(2·80 to 3·97)
2·21% 
(1·67 to 2·82)
Brunei 770 
(693 to 849)
1914 
(1725 to 2111)
1·7% 
(1·5 to 1·8)
90·5% 
(87·0 to 93·1)
5·3% 
(4·3 to 6·8)
0·0% 
(0·0 to 0·0)
–0·36% 
(–0·96 to 0·24)
–2·11% 
(–2·70 to –1·52)
–1·20% 
(–1·80 to –0·61)
Bulgaria 681 
(630 to 733)
1786 
(1653 to 1922)
6·8% 
(6·3 to 7·4)
50·9% 
(46·9 to 54·6)
47·4% 
(43·8 to 51·6)
0·1% 
(0·1 to 0·2)
5·65% 
(4·94 to 6·31)
6·38% 
(5·66 to 7·04)
2·91% 
(2·21 to 3·55)
Burkina Faso 37 
(32 to 44)
103 
(88 to 121)
4·4% 
(3·8 to 5·2)
35·9% 
(28·2 to 43·5)
35·4% 
(27·8 to 44·3)
22·3% 
(18·9 to 25·9)
6·61% 
(5·43 to 7·90)
3·51% 
(2·37 to 4·77)
0·55% 
(–0·56 to 1·77)
Burundi 28 
(25 to 31)
61 
(55 to 69)
10·3% 
(9·3 to 11·6)
26·3% 
(21·1 to 32·1)
24·9% 
(19·2 to 31·9)
47·2% 
(42·0 to 52·2)
3·97% 
(2·89 to 5·03)
0·90% 
(–0·16 to 1·92)
1·51% 
(0·45 to 2·54)
Cambodia 76 
(62 to 93)
225 
(186 to 277)
5·9% 
(4·8 to 7·2)
23·4% 
(17·6 to 30·1)
63·2% 
(55·5 to 70·4)
12·8% 
(10·3 to 15·4)
5·09% 
(3·89 to 6·38)
2·91% 
(1·74 to 4·18)
–2·56% 
(–3·67 to –1·36)
Cameroon 58 
(46 to 74)
148 
(118 to 187)
3·2% 
(2·6 to 4·1)
15·0% 
(10·6 to 20·2)
73·3% 
(66·2 to 79·7)
9·2% 
(7·1 to 11·4)
4·31% 
(2·71 to 6·08)
1·56% 
(–0·01 to 3·27)
–0·08% 
(–1·61 to 1·61)
Canada 4875 
(4773 to 4991)
5217 
(5108 to 5341)
8·0% 
(7·9 to 8·2)
73·5% 
(72·6 to 74·4)
14·6% 
(13·9 to 15·3)
0·0% 
(0·0 to 0·0)
3·51% 
(3·31 to 3·72)
2·44% 
(2·25 to 2·66)
1·03% 
(0·84 to 1·24)
Cape Verde 157 
(134 to 182)
330 
(282 to 383)
3·7% 
(3·2 to 4·3)
64·8% 
(57·8 to 71·4)
27·4% 
(21·0 to 34·5)
5·4% 
(4·6 to 6·2)
4·98% 
(3·80 to 6·16)
3·24% 
(2·08 to 4·40)
–0·77% 
(–1·89 to 0·34)
Central African 
Republic
22 
(19 to 25)
37 
(33 to 43)
5·6% 
(4·9 to 6·4)
13·5% 
(10·1 to 17·3)
36·3% 
(28·6 to 44·5)
49·2% 
(42·9 to 55·6)
1·48% 
(0·37 to 2·65)
–0·55% 
(–1·64 to 0·60)
1·29% 
(0·17 to 2·45)
Chad 36 
(29 to 44)
99 
(81 to 120)
3·1% 
(2·5 to 3·8)
21·9% 
(16·0 to 28·6)
58·0% 
(48·9 to 66·8)
14·8% 
(12·1 to 18·0)
3·83% 
(2·39 to 5·36)
0·18% 
(–1·20 to 1·67)
–2·73% 
(–4·07 to –1·29)
Chile 1244 
(1193 to 1294)
2199 
(2109 to 2288)
6·8% 
(6·6 to 7·1)
58·5% 
(56·3 to 60·7)
34·7% 
(32·6 to 36·7)
0·0% 
(0·0 to 0·0)
5·78% 
(5·32 to 6·22)
4·55% 
(4·10 to 4·99)
1·57% 
(1·13 to 2·00)
China 436 
(391 to 487)
808 
(723 to 902)
5·0% 
(4·5 to 5·6)
58·8% 
(53·3 to 64·2)
35·3% 
(30·3 to 40·1)
0·0% 
(0·0 to 0·0)
10·84% 
(9·66 to 12·04)
10·25% 
(9·08 to 11·44)
1·53% 
(0·46 to 2·63)
Colombia 358 
(315 to 399)
853 
(751 to 950)
3·9% 
(3·4 to 4·3)
65·1% 
(59·1 to 71·3)
20·6% 
(16·3 to 25·5)
0·1% 
(0·1 to 0·1)
2·06% 
(1·19 to 2·90)
0·81% 
(–0·05 to 1·64)
–1·24% 
(–2·08 to –0·43)
Comoros 80 
(66 to 96)
157 
(130 to 189)
6·3% 
(5·2 to 7·6)
12·8% 
(9·4 to 16·9)
68·4% 
(61·8 to 74·2)
17·7% 
(14·6 to 21·2)
0·85% 
(–0·34 to 2·07)
–1·58% 
(–2·74 to –0·39)
–1·56% 
(–2·72 to –0·37)
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Congo (Brazzaville) 79 
(65 to 94)
235 
(194 to 281)
2·0% 
(1·7 to 2·4)
46·9% 
(37·7 to 56·4)
44·6% 
(35·4 to 54·2)
4·4% 
(3·6 to 5·2)
5·76% 
(4·49 to 7·15)
3·07% 
(1·83 to 4·43)
2·22% 
(1·00 to 3·57)
Costa Rica 948 
(891 to 1002)
1416 
(1331 to 1498)
8·1% 
(7·6 to 8·5)
72·7% 
(69·6 to 75·7)
22·1% 
(19·4 to 25·0)
2·5% 
(2·3 to 2·6)
5·72% 
(5·18 to 6·25)
4·11% 
(3·57 to 4·62)
1·53% 
(1·01 to 2·03)
Côte d’Ivoire 77 
(63 to 92)
178 
(147 to 214)
4·1% 
(3·4 to 5·0)
23·6% 
(17·9 to 29·8)
43·3% 
(34·3 to 52·4)
14·5% 
(11·9 to 17·4)
2·18% 
(0·87 to 3·41)
–0·19% 
(–1·47 to 1·02)
–0·97% 
(–2·23 to 0·23)
Croatia 939 
(885 to 1005)
1707 
(1609 to 1828)
5·5% 
(5·2 to 5·9)
77·7% 
(74·3 to 80·5)
15·2% 
(12·8 to 17·4)
1·0% 
(0·9 to 1·1)
2·34% 
(1·81 to 2·86)
2·78% 
(2·25 to 3·30)
0·25% 
(–0·26 to 0·76)
Cuba 1128 
(1047 to 1228)
2470 
(2292 to 2689)
15·0% 
(13·9 to 16·3)
83·3% 
(77·8 to 87·4)
9·3% 
(fv7·4 to 11·4)
0·1% 
(0·1 to 0·1)
8·39% 
(7·56 to 9·18)
8·14% 
(7·31 to 8·93)
4·05% 
(3·26 to 4·81)
Cyprus 1226 
(1161 to 1293)
1712 
(1622 to 1805)
3·9% 
(3·7 to 4·1)
42·8% 
(40·3 to 45·3)
45·3% 
(42·4 to 48·1)
0·0% 
(0·0 to 0·0)
3·62% 
(3·16 to 4·03)
2·22% 
(1·77 to 2·63)
1·46% 
(1·01 to 1·86)
Czech Republic 1515 
(1457 to 1578)
2511 
(2414 to 2615)
5·7% 
(5·5 to 6·0)
82·0% 
(80·3 to 83·9)
14·8% 
(13·4 to 16·5)
0·0% 
(0·0 to 0·0)
3·38% 
(2·99 to 3·76)
3·22% 
(2·83 to 3·60)
0·84% 
(0·47 to 1·22)
Democratic Republic 
of the Congo
19 
(17 to 23)
30 
(26 to 36)
4·0% 
(3·4 to 4·7)
14·8% 
(11·1 to 19·2)
41·2% 
(32·6 to 50·1)
36·0% 
(30·3 to 41·5)
5·25% 
(3·66 to 6·87)
1·99% 
(0·45 to 3·56)
1·92% 
(0·38 to 3·49)
Denmark 6195 
(6033 to 6363)
5240 
(5103 to 5382)
8·6% 
(8·4 to 8·8)
84·1% 
(83·4 to 84·9)
13·7% 
(13·1 to 14·3)
0·0% 
(0·0 to 0·0)
2·89% 
(2·65 to 3·12)
2·45% 
(2·21 to 2·68)
1·42% 
(1·19 to 1·65)
Djibouti 66 
(57 to 77)
124 
(107 to 144)
3·6% 
(3·1 to 4·2)
52·7% 
(45·1 to 60·2)
23·5% 
(16·9 to 30·9)
22·9% 
(19·6 to 26·5)
1·46% 
(0·26 to 2·60)
–0·17% 
(–1·35 to 0·94)
–1·28% 
(–2·45 to –0·18)
Dominica 438 
(397 to 479)
638 
(580 to 698)
5·5% 
(5·0 to 6·0)
66·4% 
(62·0 to 70·7)
31·4% 
(27·2 to 35·8)
0·8% 
(0·7 to 0·9)
1·45% 
(0·76 to 2·09)
1·13% 
(0·44 to 1·77)
–0·60% 
(–1·28 to 0·03)
Dominican Republic 420 
(377 to 467)
995 
(894 to 1107)
5·1% 
(4·6 to 5·7)
45·3% 
(40·3 to 50·7)
44·1% 
(38·4 to 49·9)
1·5% 
(1·3 to 1·6)
6·45% 
(5·56 to 7·35)
4·98% 
(4·10 to 5·86)
1·05% 
(0·20 to 1·90)
Ecuador 536 
(489 to 586)
1015 
(925 to 1110)
8·7% 
(8·0 to 9·6)
51·1% 
(46·4 to 55·8)
41·4% 
(36·8 to 46·4)
0·2% 
(0·2 to 0·2)
6·50% 
(5·71 to 7·34)
4·69% 
(3·92 to 5·52)
3·21% 
(2·44 to 4·02)
Egypt 125 
(103 to 150)
577 
(477 to 695)
3·7% 
(3·1 to 4·5)
31·5% 
(24·5 to 38·8)
60·2% 
(51·8 to 68·5)
0·5% 
(0·4 to 0·6)
3·45% 
(2·15 to 4·75)
1·54% 
(0·26 to 2·82)
–0·86% 
(–2·11 to 0·39)
El Salvador 313 
(279 to 349)
656 
(585 to 732)
7·2% 
(6·4 to 8·0)
64·4% 
(58·5 to 69·7)
27·6% 
(22·7 to 32·9)
1·9% 
(1·7 to 2·1)
2·31% 
(1·46 to 3·09)
1·82% 
(0·98 to 2·61)
0·29% 
(–0·54 to 1·06)
Equatorial Guinea 310 
(275 to 351)
797 
(708 to 903)
1·6% 
(1·4 to 1·8)
21·5% 
(17·4 to 25·8)
71·6% 
(66·4 to 76·1)
2·8% 
(2·4 to 3·1)
9·04% 
(7·92 to 10·17)
5·74% 
(4·65 to 6·84)
–6·21% 
(–7·17 to –5·24)
Eritrea 30 
(24 to 37)
46 
(37 to 57)
4·4% 
(3·5 to 5·4)
20·3% 
(14·9 to 26·9)
63·0% 
(53·8 to 70·9)
14·8% 
(11·8 to 18·1)
0·24% 
(–1·19 to 1·71)
–2·20% 
(–3·60 to –0·77)
–2·07% 
(–3·47 to –0·63)
Estonia 1392 
(1338 to 1451)
2051 
(1972 to 2137)
6·2% 
(5·9 to 6·4)
75·5% 
(73·6 to 77·3)
22·7% 
(21·0 to 24·5)
0·0% 
(0·0 to 0·0)
3·80% 
(3·37 to 4·24)
4·28% 
(3·85 to 4·72)
–0·14% 
(–0·55 to 0·28)
eSwatini 329 
(297 to 365)
876 
(792 to 972)
6·6% 
(5·9 to 7·3)
60·3% 
(55·8 to 64·8)
9·8% 
(7·0 to 13·2)
22·5% 
(20·3 to 24·9)
6·39% 
(5·29 to 7·50)
4·63% 
(3·54 to 5·71)
2·87% 
(1·80 to 3·94)
Ethiopia 31 
(26 to 37)
83 
(70 to 99)
5·4% 
(4·6 to 6·5)
22·6% 
(17·1 to 28·9)
34·2% 
(25·5 to 43·5)
26·3% 
(21·7 to 30·7)
8·94% 
(7·61 to 10·35)
5·83% 
(4·53 to 7·19)
0·55% 
(–0·68 to 1·85)
Federated States of 
Micronesia
130 
(109 to 154)
144 
(121 to 171)
3·9% 
(3·3 to 4·7)
84·1% 
(79·9 to 87·5)
7·7% 
(5·2 to 11·1)
8·1% 
(6·8 to 9·6)
1·56% 
(0·33 to 2·77)
1·79% 
(0·56 to 3·00)
1·54% 
(0·31 to 2·75)
Fiji 200 
(173 to 234)
350 
(303 to 408)
3·6% 
(3·1 to 4·2)
61·8% 
(53·9 to 68·8)
20·3% 
(15·0 to 27·0)
4·5% 
(3·9 to 5·2)
3·13% 
(2·05 to 4·22)
2·48% 
(1·41 to 3·57)
1·06% 
(0·01 to 2·14)
Finland 4656 
(4550 to 4764)
4235 
(4139 to 4333)
8·4% 
(8·2 to 8·6)
77·4% 
(76·4 to 78·3)
20·2% 
(19·4 to 21·1)
0·0% 
(0·0 to 0·0)
3·37% 
(3·16 to 3·60)
3·00% 
(2·79 to 3·23)
1·24% 
(1·03 to 1·47)
France 4945 
(4826 to 5063)
5148 
(5023 to 5270)
9·8% 
(9·5 to 10·0)
80·6% 
(79·2 to 81·9)
9·6% 
(9·0 to 10·2)
0·0% 
(0·0 to 0·0)
2·45% 
(2·23 to 2·65)
1·88% 
(1·67 to 2·09)
0·87% 
(0·65 to 1·07)
Gabon 281 
(245 to 321)
649 
(566 to 742)
2·2% 
(1·9 to 2·5)
62·1% 
(55·4 to 68·3)
24·4% 
(19·2 to 29·9)
1·1% 
(1·0 to 1·3)
1·57% 
(0·72 to 2·42)
–0·82% 
(–1·65 to 0·00)
–0·01% 
(–0·84 to 0·83)
Georgia 319 
(282 to 360)
851 
(751 to 959)
6·1% 
(5·4 to 6·9)
34·0% 
(28·4 to 39·6)
59·2% 
(53·1 to 65·0)
1·3% 
(1·2 to 1·5)
8·15% 
(6·87 to 9·40)
9·29% 
(8·00 to 10·55)
2·21% 
(1·00 to 3·39)
Germany 5263 
(5095 to 5435)
5619 
(5440 to 5803)
9·6% 
(9·3 to 9·9)
84·6% 
(83·5 to 85·7)
12·4% 
(11·8 to 13·1)
0·0% 
(0·0 to 0·0)
1·26% 
(1·01 to 1·52)
1·20% 
(0·95 to 1·46)
–0·12% 
(–0·37 to 0·13)
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Ghana 75 
(63 to 88)
210 
(176 to 247)
3·6% 
(3·0 to 4·2)
39·9% 
(32·0 to 47·5)
39·4% 
(31·3 to 48·2)
13·7% 
(11·5 to 16·2)
6·39% 
(5·05 to 7·71)
3·75% 
(2·44 to 5·03)
0·57% 
(–0·70 to 1·81)
Greece 1693 
(1601 to 1790)
2392 
(2263 to 2529)
6·4% 
(6·0 to 6·7)
59·7% 
(56·8 to 62·7)
35·6% 
(32·6 to 38·3)
0·0% 
(0·0 to 0·0)
1·17% 
(0·76 to 1·57)
1·06% 
(0·65 to 1·46)
0·47% 
(0·06 to 0·86)
Greenland 4457 
(4203 to 4731)
3516 
(3316 to 3732)
8·1% 
(7·6 to 8·6)
100·0% 
(100·0 to 100·0)
0·0% 
(0·0 to 0·0)
0·0% 
(0·0 to 0·0)
2·51% 
(1·30 to 3·60)
2·52% 
(1·32 to 3·61)
–0·04% 
(–1·22 to 1·02)
Grenada 486 
(438 to 536)
723 
(652 to 797)
5·0% 
(4·5 to 5·5)
40·9% 
(36·2 to 45·7)
58·6% 
(53·9 to 63·3)
0·5% 
(0·4 to 0·5)
0·82% 
(0·13 to 1·51)
0·56% 
(–0·12 to 1·25)
–2·31% 
(–2·98 to –1·64)
Guam 1990 
(1548 to 2480)
1990 
(1548 to 2480)
5·5% 
(4·3 to 6·9)
87·4% 
(81·7 to 91·6)
8·8% 
(5·8 to 12·8)
0·0% 
(0·0 to 0·0)
2·88% 
(1·09 to 4·53)
2·01% 
(0·23 to 3·65)
0·97% 
(–0·79 to 2·59)
Guatemala 262 
(227 to 301)
479 
(415 to 550)
6·8% 
(5·9 to 7·8)
36·6% 
(30·7 to 42·9)
54·8% 
(47·5 to 61·1)
1·2% 
(1·1 to 1·4)
5·07% 
(4·03 to 6·06)
2·77% 
(1·75 to 3·74)
1·46% 
(0·46 to 2·42)
Guinea 44 
(37 to 53)
119 
(99 to 143)
6·0% 
(5·0 to 7·2)
11·1% 
(8·0 to 15·1)
53·4% 
(44·3 to 62·2)
25·7% 
(21·0 to 30·4)
6·11% 
(4·78 to 7·58)
3·49% 
(2·19 to 4·92)
1·82% 
(0·54 to 3·23)
Guinea-Bissau 49 
(43 to 57)
110 
(95 to 128)
6·1% 
(5·3 to 7·1)
34·4% 
(28·0 to 41·5)
33·9% 
(26·3 to 41·9)
31·7% 
(27·2 to 36·4)
1·71% 
(0·76 to 2·71)
–0·66% 
(–1·59 to 0·31)
–0·70% 
(–1·62 to 0·28)
Guyana 208 
(180 to 239)
377 
(327 to 434)
4·5% 
(3·9 to 5·2)
56·6% 
(49·8 to 63·7)
38·5% 
(31·4 to 45·4)
4·8% 
(4·2 to 5·5)
3·12% 
(2·06 to 4·21)
3·02% 
(1·96 to 4·11)
0·11% 
(–0·92 to 1·17)
Haiti 47 
(42 to 54)
113 
(100 to 130)
5·4% 
(4·7 to 6·1)
13·1% 
(9·8 to 16·7)
35·6% 
(28·1 to 43·7)
47·1% 
(40·9 to 52·9)
0·55% 
(–0·34 to 1·54)
–1·13% 
(–2·01 to –0·16)
–1·08% 
(–1·96 to –0·11)
Honduras 193 
(165 to 222)
401 
(343 to 462)
7·2% 
(6·1 to 8·3)
43·1% 
(36·2 to 50·6)
47·3% 
(39·3 to 54·7)
3·2% 
(2·7 to 3·7)
5·18% 
(4·04 to 6·28)
3·15% 
(2·03 to 4·23)
1·54% 
(0·44 to 2·60)
Hungary 1029 
(976 to 1081)
2133 
(2024 to 2242)
5·8% 
(5·5 to 6·1)
66·1% 
(63·5 to 68·6)
29·3% 
(27·0 to 31·7)
0·0% 
(0·0 to 0·0)
2·34% 
(1·91 to 2·77)
2·54% 
(2·10 to 2·97)
0·04% 
(–0·39 to 0·46)
Iceland 6307 
(6123 to 6494)
4347 
(4220 to 4476)
10·6% 
(10·3 to 10·9)
81·4% 
(80·4 to 82·3)
17·0% 
(16·1 to 18·0)
0·0% 
(0·0 to 0·0)
3·52% 
(3·26 to 3·79)
2·47% 
(2·22 to 2·74)
0·06% 
(–0·18 to 0·33)
India 65 
(52 to 80)
247 
(199 to 305)
3·0% 
(2·4 to 3·6)
25·4% 
(18·5 to 33·4)
64·2% 
(54·2 to 72·6)
0·9% 
(0·7 to 1·0)
6·07% 
(4·48 to 7·77)
4·46% 
(2·90 to 6·14)
–0·84% 
(–2·32 to 0·75)
Indonesia 116 
(96 to 141)
388 
(321 to 470)
2·3% 
(1·9 to 2·8)
40·3% 
(31·6 to 49·4)
40·1% 
(31·0 to 49·5)
0·7% 
(0·6 to 0·8)
5·94% 
(4·38 to 7·43)
4·59% 
(3·05 to 6·06)
1·70% 
(0·20 to 3·13)
Iran 420 
(375 to 471)
1707 
(1524 to 1915)
4·8% 
(4·3 to 5·4)
50·5% 
(44·5 to 56·1)
37·6% 
(31·9 to 43·4)
0·0% 
(0·0 to 0·0)
7·80% 
(6·92 to 8·76)
6·31% 
(5·44 to 7·25)
4·27% 
(3·41 to 5·19)
Iraq 157 
(133 to 187)
505 
(427 to 601)
2·0% 
(1·7 to 2·4)
26·2% 
(20·3 to 32·5)
73·5% 
(67·2 to 79·4)
0·3% 
(0·2 to 0·3)
10·14% 
(8·68 to 11·74)
6·70% 
(5·28 to 8·25)
1·56% 
(0·20 to 3·03)
Ireland 5097 
(4901 to 5288)
5194 
(4995 to 5389)
6·2% 
(5·9 to 6·4)
71·9% 
(70·4 to 73·4)
13·2% 
(12·3 to 14·2)
0·0% 
(0·0 to 0·0)
6·60% 
(6·12 to 7·05)
5·33% 
(4·86 to 5·78)
0·92% 
(0·47 to 1·35)
Israel 2757 
(2684 to 2827)
2597 
(2528 to 2663)
6·7% 
(6·5 to 6·9)
63·6% 
(62·2 to 65·1)
23·2% 
(21·9 to 24·4)
0·0% 
(0·0 to 0·0)
3·75% 
(3·52 to 3·97)
1·65% 
(1·43 to 1·87)
0·03% 
(–0·20 to 0·24)
Italy 3059 
(2976 to 3141)
3462 
(3368 to 3555)
7·4% 
(7·2 to 7·6)
74·4% 
(73·3 to 75·6)
23·1% 
(22·0 to 24·2)
0·0% 
(0·0 to 0·0)
1·70% 
(1·48 to 1·89)
1·40% 
(1·19 to 1·60)
1·15% 
(0·93 to 1·34)
Jamaica 314 
(273 to 357)
569 
(496 to 647)
5·4% 
(4·7 to 6·1)
60·0% 
(53·1 to 66·5)
21·0% 
(16·5 to 26·4)
1·7% 
(1·5 to 2·0)
1·76% 
(0·86 to 2·61)
1·16% 
(0·26 to 2·00)
1·33% 
(0·43 to 2·17)
Japan 4175 
(4065 to 4278)
4667 
(4543 to 4782)
7·2% 
(7·0 to 7·4)
83·7% 
(82·7 to 84·6)
13·3% 
(12·6 to 14·1)
0·0% 
(0·0 to 0·0)
3·94% 
(3·67 to 4·20)
3·89% 
(3·61 to 4·15)
3·07% 
(2·80 to 3·33)
Jordan 224 
(198 to 253)
509 
(450 to 574)
5·1% 
(4·6 to 5·8)
65·7% 
(59·8 to 70·7)
26·2% 
(21·5 to 31·4)
2·1% 
(1·8 to 2·3)
1·86% 
(1·06 to 2·67)
–0·93% 
(–1·70 to –0·14)
–2·26% 
(–3·03 to –1·48)
Kazakhstan 295 
(260 to 335)
868 
(763 to 983)
2·1% 
(1·8 to 2·3)
61·3% 
(54·6 to 68·1)
32·6% 
(26·3 to 39·0)
0·8% 
(0·7 to 0·9)
2·95% 
(2·02 to 3·84)
2·43% 
(1·50 to 3·31)
–2·53% 
(–3·41 to –1·69)
Kenya 82 
(70 to 96)
168 
(143 to 196)
6·3% 
(5·4 to 7·4)
33·9% 
(26·3 to 41·6)
27·1% 
(20·1 to 35·0)
23·9% 
(20·3 to 27·8)
4·09% 
(2·87 to 5·39)
1·51% 
(0·32 to 2·78)
0·19% 
(–0·99 to 1·44)
Kiribati 198 
(176 to 224)
233 
(207 to 263)
9·1% 
(8·1 to 10·3)
64·6% 
(59·1 to 69·6)
13·6% 
(9·8 to 18·1)
17·8% 
(15·7 to 20·0)
2·45% 
(1·55 to 3·44)
0·78% 
(–0·11 to 1·75)
0·55% 
(–0·33 to 1·52)
Kuwait 1279 
(1140 to 1433)
2959 
(2637 to 3314)
2·7% 
(2·4 to 3·1)
83·2% 
(80·3 to 85·8)
15·2% 
(12·8 to 17·9)
0·0% 
(0·0 to 0·0)
3·56% 
(2·79 to 4·33)
–0·58% 
(–1·32 to 0·16)
–0·02% 
(–0·76 to 0·73)
(Table 1 continues on next page)
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Kyrgyzstan 79 
(65 to 96)
262 
(217 to 318)
5·5% 
(4·6 to 6·7)
40·0% 
(31·7 to 48·8)
52·4% 
(43·3 to 61·3)
7·6% 
(6·2 to 9·1)
4·48% 
(3·17 to 5·80)
3·14% 
(1·85 to 4·45)
–0·09% 
(–1·34 to 1·18)
Laos 52 
(43 to 62)
157 
(130 to 189)
2·4% 
(2·0 to 2·9)
33·4% 
(24·8 to 41·7)
48·9% 
(39·0 to 58·6)
14·3% 
(11·8 to 17·3)
4·38% 
(3·03 to 5·82)
2·34% 
(1·02 to 3·75)
–2·81% 
(–4·07 to –1·47)
Latvia 995 
(943 to 1045)
1635 
(1549 to 1717)
5·4% 
(5·1 to 5·6)
55·1% 
(52·7 to 57·7)
43·9% 
(41·4 to 46·3)
0·0% 
(0·0 to 0·0)
4·29% 
(3·76 to 4·82)
5·41% 
(4·88 to 5·95)
0·25% 
(–0·26 to 0·76)
Lebanon 486 
(437 to 540)
852 
(766 to 946)
5·3% 
(4·8 to 5·9)
51·4% 
(46·4 to 56·4)
32·5% 
(28·3 to 37·1)
0·5% 
(0·5 to 0·6)
1·90% 
(1·25 to 2·57)
–1·22% 
(–1·85 to –0·57)
–2·11% 
(–2·74 to –1·46)
Lesotho 122 
(107 to 139)
323 
(282 to 367)
7·0% 
(6·1 to 7·9)
55·8% 
(49·8 to 61·7)
15·5% 
(11·2 to 20·5)
27·3% 
(23·9 to 31·0)
6·96% 
(5·82 to 8·17)
5·86% 
(4·73 to 7·06)
2·81% 
(1·71 to 3·97)
Liberia 81 
(71 to 94)
179 
(157 to 208)
14·7% 
(12·9 to 17·1)
9·6% 
(7·0 to 12·6)
42·3% 
(34·1 to 50·9)
42·2% 
(36·2 to 48·0)
14·61% 
(12·99 to 16·34)
10·42% 
(8·85 to 12·08)
4·22% 
(2·75 to 5·80)
Libya 257 
(222 to 294)
467 
(404 to 535)
4·6% 
(4·0 to 5·3)
65·8% 
(58·5 to 72·1)
29·2% 
(23·0 to 35·7)
0·3% 
(0·2 to 0·3)
–1·18% 
(–2·01 to –0·35)
–2·27% 
(–3·10 to –1·45)
1·83% 
(0·96 to 2·68)
Lithuania 1121 
(1069 to 1176)
2044 
(1949 to 2144)
5·7% 
(5·4 to 6·0)
66·1% 
(63·8 to 68·4)
32·5% 
(30·3 to 34·8)
0·0% 
(0·0 to 0·0)
5·50% 
(4·90 to 6·10)
6·63% 
(6·03 to 7·24)
1·22% 
(0·65 to 1·80)
Luxembourg 7027 
(6713 to 7360)
6677 
(6379 to 6994)
5·2% 
(5·0 to 5·4)
82·4% 
(80·9 to 83·9)
11·3% 
(10·1 to 12·6)
0·0% 
(0·0 to 0·0)
4·75% 
(4·30 to 5·20)
3·00% 
(2·55 to 3·44)
1·15% 
(0·71 to 1·58)
Macedonia 364 
(326 to 404)
949 
(849 to 1053)
5·6% 
(5·0 to 6·2)
63·5% 
(57·8 to 68·7)
34·5% 
(29·3 to 40·2)
0·3% 
(0·3 to 0·3)
1·14% 
(0·36 to 1·92)
0·87% 
(0·10 to 1·65)
–1·68% 
(–2·43 to –0·93)
Madagascar 23 
(20 to 27)
81 
(68 to 94)
4·1% 
(3·5 to 4·8)
46·6% 
(38·4 to 55·5)
27·1% 
(19·3 to 35·2)
19·1% 
(16·2 to 22·3)
3·45% 
(2·28 to 4·58)
0·45% 
(–0·68 to 1·55)
0·52% 
(–0·61 to 1·62)
Malawi 39 
(36 to 42)
141 
(130 to 153)
6·6% 
(6·1 to 7·2)
23·4% 
(18·5 to 28·2)
9·8% 
(6·9 to 13·2)
61·0% 
(56·1 to 66·0)
8·37% 
(7·56 to 9·14)
5·36% 
(4·57 to 6·10)
3·88% 
(3·10 to 4·61)
Malaysia 407 
(366 to 455)
1151 
(1032 to 1284)
3·0% 
(2·7 to 3·3)
52·2% 
(46·6 to 57·8)
36·2% 
(30·7 to 41·8)
0·0% 
(0·0 to 0·0)
6·96% 
(6·06 to 7·83)
4·96% 
(4·08 to 5·82)
2·20% 
(1·34 to 3·03)
Maldives 974 
(903 to 1047)
1539 
(1426 to 1653)
10·0% 
(9·3 to 10·8)
70·5% 
(67·1 to 73·8)
20·1% 
(17·6 to 22·9)
0·2% 
(0·2 to 0·2)
6·60% 
(5·91 to 7·23)
4·44% 
(3·77 to 5·06)
0·91% 
(0·26 to 1·51)
Mali 33 
(28 to 38)
84 
(73 to 97)
3·1% 
(2·7 to 3·6)
24·7% 
(19·0 to 30·6)
37·1% 
(29·6 to 46·1)
36·8% 
(31·8 to 42·3)
5·45% 
(4·28 to 6·61)
2·34% 
(1·20 to 3·46)
–0·64% 
(–1·75 to 0·44)
Malta 2799 
(2725 to 2879)
4037 
(3932 to 4154)
8·7% 
(8·5 to 9·0)
62·3% 
(60·9 to 63·7)
35·5% 
(34·2 to 36·8)
0·0% 
(0·0 to 0·0)
5·73% 
(5·42 to 6·05)
5·12% 
(4·81 to 5·44)
2·26% 
(1·96 to 2·57)
Marshall Islands 529 
(480 to 586)
518 
(470 to 574)
13·6% 
(12·3 to 15·0)
79·3% 
(75·2 to 83·1)
14·3% 
(11·2 to 17·9)
2·5% 
(2·3 to 2·8)
2·29% 
(1·58 to 2·99)
0·29% 
(–0·42 to 0·97)
–0·06% 
(–0·76 to 0·62)
Mauritania 56 
(46 to 67)
191 
(159 to 229)
3·2% 
(2·7 to 3·8)
36·9% 
(28·9 to 45·7)
50·4% 
(41·0 to 59·8)
8·4% 
(6·9 to 9·9)
2·92% 
(1·68 to 4·27)
0·10% 
(–1·11 to 1·41)
–1·19% 
(–2·38 to 0·10)
Mauritius 557 
(510 to 610)
1237 
(1132 to 1354)
4·6% 
(4·2 to 5·0)
44·1% 
(39·6 to 48·6)
49·3% 
(44·7 to 53·9)
0·2% 
(0·1 to 0·2)
8·11% 
(7·22 to 8·98)
7·48% 
(6·61 to 8·35)
3·60% 
(2·76 to 4·44)
Mexico 505 
(458 to 554)
1101 
(1000 to 1209)
4·2% 
(3·8 to 4·6)
52·5% 
(47·8 to 57·2)
40·0% 
(35·3 to 44·4)
0·1% 
(0·1 to 0·1)
4·10% 
(3·34 to 4·82)
2·64% 
(1·89 to 3·35)
1·25% 
(0·51 to 1·94)
Moldova 204 
(177 to 235)
498 
(432 to 574)
8·1% 
(7·0 to 9·3)
50·2% 
(42·5 to 57·5)
45·4% 
(38·1 to 53·0)
3·2% 
(2·8 to 3·7)
3·19% 
(2·11 to 4·31)
3·50% 
(2·42 to 4·63)
0·33% 
(–0·72 to 1·42)
Mongolia 150 
(129 to 175)
506 
(436 to 590)
2·8% 
(2·4 to 3·2)
52·2% 
(44·3 to 59·8)
35·5% 
(28·1 to 43·2)
9·1% 
(7·7 to 10·5)
6·11% 
(4·95 to 7·34)
4·71% 
(3·56 to 5·93)
–0·01% 
(–1·11 to 1·14)
Montenegro 603 
(554 to 656)
1325 
(1218 to 1442)
6·8% 
(6·2 to 7·4)
74·4% 
(70·3 to 78·0)
24·6% 
(21·0 to 28·7)
0·6% 
(0·6 to 0·7)
0·40% 
(–0·16 to 0·99)
0·35% 
(–0·21 to 0·94)
–3·12% 
(–3·66 to –2·55)
Morocco 185 
(159 to 216)
500 
(431 to 584)
4·8% 
(4·1 to 5·6)
43·7% 
(36·2 to 51·0)
48·6% 
(41·0 to 56·1)
3·7% 
(3·1 to 4·3)
7·89% 
(6·59 to 9·17)
6·81% 
(5·53 to 8·09)
3·55% 
(2·31 to 4·79)
Mozambique 32 
(31 to 35)
92 
(87 to 98)
4·6% 
(4·4 to 4·9)
19·5% 
(15·5 to 24·2)
5·5% 
(4·0 to 7·6)
73·3% 
(68·7 to 77·2)
8·52% 
(7·86 to 9·11)
5·40% 
(4·76 to 5·97)
–0·03% 
(–0·64 to 0·51)
Myanmar 59 
(48 to 75)
302 
(243 to 383)
3·3% 
(2·7 to 4·2)
19·6% 
(14·0 to 26·2)
71·0% 
(63·2 to 78·1)
9·4% 
(7·3 to 11·5)
13·54% 
(11·61 to 15·67)
12·46% 
(10·55 to 14·58)
3·79% 
(2·02 to 5·74)
Namibia 512 
(462 to 568)
1119 
(1009 to 1242)
7·1% 
(6·4 to 7·8)
58·7% 
(53·4 to 63·6)
8·0% 
(5·9 to 10·5)
6·7% 
(6·0 to 7·4)
3·89% 
(3·13 to 4·63)
1·89% 
(1·14 to 2·61)
–0·49% 
(–1·22 to 0·22)
(Table 1 continues on next page)
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Nepal 48 
(38 to 60)
153 
(120 to 193)
5·4% 
(4·3 to 6·9)
18·5% 
(13·4 to 24·6)
60·1% 
(50·1 to 69·1)
8·2% 
(6·4 to 10·2)
6·14% 
(4·44 to 7·80)
4·42% 
(2·76 to 6·06)
1·79% 
(0·17 to 3·38)
Netherlands 5329 
(5132 to 5527)
5603 
(5396 to 5812)
8·6% 
(8·3 to 9·0)
80·7% 
(78·8 to 82·5)
11·7% 
(10·7 to 12·8)
0·0% 
(0·0 to 0·0)
3·11% 
(2·77 to 3·43)
2·60% 
(2·25 to 2·91)
1·11% 
(0·76 to 1·41)
New Zealand 4276 
(4168 to 4376)
4002 
(3901 to 4096)
9·2% 
(8·9 to 9·4)
78·7% 
(77·6 to 79·7)
13·5% 
(12·7 to 14·4)
0·0% 
(0·0 to 0·0)
3·88% 
(3·66 to 4·11)
2·81% 
(2·59 to 3·04)
1·10% 
(0·88 to 1·32)
Nicaragua 184 
(159 to 212)
502 
(434 to 578)
8·0% 
(7·0 to 9·3)
56·2% 
(49·1 to 63·3)
32·7% 
(25·8 to 40·2)
9·0% 
(7·8 to 10·3)
4·76% 
(3·71 to 5·86)
3·27% 
(2·24 to 4·35)
0·57% 
(–0·43 to 1·63)
Niger 27 
(22 to 33)
67 
(55 to 82)
5·4% 
(4·4 to 6·5)
24·9% 
(18·5 to 31·6)
54·7% 
(46·1 to 63·5)
15·0% 
(12·2 to 18·1)
4·57% 
(3·12 to 6·01)
0·75% 
(–0·64 to 2·14)
–0·32% 
(–1·70 to 1·06)
Nigeria 71 
(57 to 89)
199 
(158 to 248)
2·4% 
(1·9 to 3·0)
14·5% 
(10·6 to 19·2)
75·2% 
(69·0 to 80·8)
8·6% 
(6·8 to 10·7)
6·75% 
(4·88 to 8·51)
4·01% 
(2·19 to 5·73)
0·81% 
(–0·95 to 2·47)
North Korea 66 
(54 to 80)
44 
(35 to 53)
5·8% 
(4·7 to 7·1)
61·9% 
(51·7 to 72·2)
36·8% 
(26·6 to 47·2)
0·3% 
(0·3 to 0·4)
0·92% 
(–0·45 to 2·37)
0·26% 
(–1·10 to 1·70)
0·31% 
(–1·06 to 1·75)
Northern Mariana 
Islands
261 
(208 to 326)
261 
(208 to 326)
1·2% 
(1·0 to 1·5)
84·2% 
(77·6 to 88·8)
14·6% 
(10·1 to 21·1)
0·0% 
(0·0 to 0·0)
–1·02% 
(–2·62 to 0·61)
–4·24% 
(–5·79 to –2·66)
–3·67% 
(–5·23 to –2·09)
Norway 8269 
(7946 to 8608)
7708 
(7407 to 8024)
7·1% 
(6·8 to 7·4)
85·2% 
(84·3 to 86·1)
14·5% 
(13·6 to 15·3)
0·0% 
(0·0 to 0·0)
4·03% 
(3·67 to 4·40)
3·10% 
(2·75 to 3·47)
1·89% 
(1·54 to 2·26)
Oman 764 
(704 to 833)
1861 
(1716 to 2029)
3·4% 
(3·1 to 3·7)
89·1% 
(86·6 to 91·2)
5·9% 
(4·5 to 7·4)
0·0% 
(0·0 to 0·0)
4·54% 
(3·86 to 5·24)
0·96% 
(0·31 to 1·64)
0·69% 
(0·03 to 1·37)
Pakistan 41 
(33 to 51)
142 
(115 to 177)
2·7% 
(2·2 to 3·3)
26·2% 
(19·7 to 34·4)
62·7% 
(53·1 to 71·0)
8·3% 
(6·6 to 10·2)
3·42% 
(1·96 to 4·98)
1·25% 
(–0·18 to 2·77)
–0·57% 
(–1·98 to 0·92)
Palestine 320 
(277 to 373)
113 
(98 to 131)
10·6% 
(9·1 to 12·3)
38·7% 
(32·5 to 45·0)
39·1% 
(32·7 to 45·7)
1·8% 
(1·6 to 2·1)
5·93% 
(4·69 to 7·18)
2·44% 
(1·24 to 3·64)
1·05% 
(–0·13 to 2·24)
Panama 1078 
(1014 to 1142)
1872 
(1759 to 1982)
8·1% 
(7·6 to 8·6)
64·6% 
(61·3 to 67·9)
28·6% 
(25·7 to 31·8)
0·1% 
(0·1 to 0·1)
6·11% 
(5·60 to 6·64)
4·23% 
(3·74 to 4·76)
0·11% 
(–0·37 to 0·62)
Papua New Guinea 59 
(49 to 71)
73 
(61 to 88)
1·8% 
(1·5 to 2·2)
72·8% 
(67·5 to 78·1)
7·4% 
(5·0 to 10·3)
18·4% 
(15·1 to 21·8)
4·15% 
(2·69 to 5·62)
1·70% 
(0·28 to 3·14)
0·85% 
(–0·56 to 2·27)
Paraguay 343 
(302 to 392)
804 
(706 to 916)
6·5% 
(5·7 to 7·4)
52·1% 
(45·7 to 58·0)
37·0% 
(31·2 to 43·3)
0·6% 
(0·5 to 0·6)
5·58% 
(4·61 to 6·49)
3·91% 
(2·95 to 4·81)
2·29% 
(1·35 to 3·18)
Peru 337 
(299 to 378)
683 
(605 to 765)
4·5% 
(4·0 to 5·1)
62·7% 
(56·4 to 68·9)
29·1% 
(23·5 to 34·8)
0·3% 
(0·2 to 0·3)
5·08% 
(4·16 to 5·99)
3·59% 
(2·68 to 4·49)
0·40% 
(–0·48 to 1·27)
Philippines 124 
(101 to 151)
361 
(294 to 441)
3·7% 
(3·0 to 4·5)
30·9% 
(23·7 to 39·0)
54·4% 
(44·9 to 63·0)
1·0% 
(0·8 to 1·2)
6·24% 
(4·85 to 7·62)
4·28% 
(2·93 to 5·64)
1·36% 
(0·05 to 2·69)
Poland 908 
(863 to 956)
1857 
(1765 to 1955)
5·1% 
(4·9 to 5·4)
69·9% 
(67·2 to 72·6)
23·2% 
(20·9 to 25·5)
0·0% 
(0·0 to 0·0)
4·98% 
(4·47 to 5·51)
4·92% 
(4·42 to 5·45)
0·85% 
(0·36 to 1·36)
Portugal 1954 
(1882 to 2029)
2649 
(2552 to 2751)
7·4% 
(7·1 to 7·7)
66·2% 
(64·4 to 67·8)
27·8% 
(26·3 to 29·4)
0·0% 
(0·0 to 0·0)
2·73% 
(2·41 to 3·04)
2·53% 
(2·21 to 2·84)
1·47% 
(1·16 to 1·77)
Puerto Rico 1364 
(1210 to 1561)
1671 
(1483 to 1913)
4·5% 
(3·9 to 5·1)
64·9% 
(56·7 to 72·3)
26·5% 
(19·5 to 34·1)
0·0% 
(0·0 to 0·0)
1·47% 
(0·31 to 2·66)
1·46% 
(0·30 to 2·65)
0·24% 
(–0·90 to 1·42)
Qatar 2064 
(1900 to 2219)
4145 
(3815 to 4456)
2·4% 
(2·2 to 2·5)
82·8% 
(80·6 to 84·9)
7·8% 
(6·4 to 9·3)
0·0% 
(0·0 to 0·0)
9·14% 
(8·51 to 9·77)
1·61% 
(1·02 to 2·20)
–0·47% 
(–1·04 to 0·11)
Romania 537 
(490 to 587)
1181 
(1077 to 1291)
4·3% 
(4·0 to 4·8)
78·2% 
(74·0 to 81·8)
20·8% 
(17·1 to 24·9)
0·1% 
(0·1 to 0·1)
4·56% 
(3·83 to 5·32)
5·41% 
(4·67 to 6·17)
1·88% 
(1·17 to 2·62)
Russia 574 
(527 to 621)
1470 
(1350 to 1592)
3·5% 
(3·2 to 3·8)
58·1% 
(53·9 to 62·6)
39·2% 
(34·7 to 43·4)
0·0% 
(0·0 to 0·0)
2·52% 
(1·87 to 3·22)
2·54% 
(1·89 to 3·24)
–0·62% 
(–1·25 to 0·06)
Rwanda 44 
(39 to 50)
121 
(107 to 138)
5·0% 
(4·4 to 5·7)
37·0% 
(30·6 to 44·2)
8·1% 
(5·9 to 11·1)
43·6% 
(37·9 to 49·0)
7·70% 
(6·47 to 8·86)
4·46% 
(3·26 to 5·59)
–0·21% 
(–1·36 to 0·87)
Saint Lucia 511 
(464 to 559)
800 
(726 to 875)
5·5% 
(5·0 to 6·0)
39·1% 
(34·8 to 43·4)
47·9% 
(43·4 to 52·6)
7·1% 
(6·4 to 7·8)
1·61% 
(0·97 to 2·23)
0·58% 
(–0·05 to 1·20)
–0·28% 
(–0·91 to 0·33)
Saint Vincent and 
the Grenadines
277 
(245 to 310)
453 
(400 to 507)
3·7% 
(3·3 to 4·2)
68·3% 
(62·9 to 73·2)
18·7% 
(14·3 to 23·8)
10·4% 
(9·3 to 11·7)
1·52% 
(0·72 to 2·37)
1·49% 
(0·68 to 2·33)
–0·72% 
(–1·51 to 0·10)
Samoa 232 
(205 to 262)
320 
(283 to 363)
4·9% 
(4·3 to 5·6)
76·7% 
(72·4 to 80·6)
12·2% 
(8·9 to 16·4)
10·1% 
(8·9 to 11·3)
3·30% 
(2·38 to 4·26)
2·61% 
(1·70 to 3·56)
0·42% 
(–0·48 to 1·35)
(Table 1 continues on next page)
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São Tomé and 
Príncipe
102 
(90 to 114)
173 
(154 to 195)
6·4% 
(5·7 to 7·2)
42·9% 
(37·1 to 48·8)
18·2% 
(13·7 to 23·7)
37·2% 
(32·9 to 41·8)
1·99% 
(1·06 to 2·89)
–0·18% 
(–1·09 to 0·70)
–1·78% 
(–2·68 to –0·93)
Saudi Arabia 1257 
(1185 to 1336)
3200 
(3018 to 3402)
4·5% 
(4·3 to 4·8)
69·5% 
(66·9 to 71·9)
14·2% 
(12·4 to 16·2)
0·0% 
(0·0 to 0·0)
6·77% 
(6·20 to 7·38)
4·30% 
(3·74 to 4·89)
3·65% 
(3·10 to 4·24)
Senegal 69 
(57 to 83)
172 
(143 to 207)
5·1% 
(4·3 to 6·2)
30·0% 
(22·9 to 37·9)
48·7% 
(39·4 to 58·3)
13·4% 
(11·1 to 16·0)
4·51% 
(3·24 to 5·93)
1·62% 
(0·39 to 3·00)
0·13% 
(–1·09 to 1·49)
Serbia 462 
(420 to 504)
1121 
(1018 to 1223)
6·1% 
(5·5 to 6·6)
58·0% 
(53·0 to 62·7)
40·0% 
(35·2 to 45·0)
0·5% 
(0·5 to 0·6)
4·99% 
(4·14 to 5·78)
5·58% 
(4·72 to 6·38)
1·95% 
(1·12 to 2·72)
Seychelles 534 
(494 to 573)
1002 
(926 to 1075)
3·5% 
(3·2 to 3·8)
97·8% 
(97·1 to 98·4)
2·1% 
(1·5 to 2·8)
0·1% 
(0·1 to 0·1)
0·65% 
(0·10 to 1·19)
–0·48% 
(–1·01 to 0·07)
–3·01% 
(–3·53 to –2·48)
Sierra Leone 82 
(71 to 96)
257 
(223 to 300)
14·9% 
(12·9 to 17·4)
9·8% 
(7·3 to 12·8)
46·4% 
(38·4 to 54·6)
39·0% 
(33·3 to 44·9)
5·74% 
(4·31 to 7·19)
2·97% 
(1·57 to 4·37)
2·33% 
(0·94 to 3·73)
Singapore 2580 
(2486 to 2673)
4240 
(4087 to 4393)
3·9% 
(3·8 to 4·1)
54·1% 
(52·4 to 55·9)
31·2% 
(29·8 to 32·7)
0·0% 
(0·0 to 0·0)
5·37% 
(5·00 to 5·73)
4·05% 
(3·67 to 4·40)
1·12% 
(0·76 to 1·46)
Slovakia 1325 
(1275 to 1379)
2334 
(2246 to 2428)
5·7% 
(5·5 to 6·0)
79·5% 
(77·5 to 81·4)
17·9% 
(16·0 to 19·8)
0·0% 
(0·0 to 0·0)
4·78% 
(4·39 to 5·18)
4·67% 
(4·29 to 5·07)
0·79% 
(0·42 to 1·18)
Slovenia 2090 
(2027 to 2156)
2857 
(2770 to 2947)
7·2% 
(7·0 to 7·4)
72·0% 
(70·2 to 73·6)
12·2% 
(11·1 to 13·4)
0·0% 
(0·0 to 0·0)
3·49% 
(3·18 to 3·78)
3·30% 
(3·00 to 3·60)
0·95% 
(0·65 to 1·24)
Solomon Islands 109 
(96 to 124)
114 
(99 to 129)
5·5% 
(4·8 to 6·3)
64·7% 
(59·7 to 69·2)
4·7% 
(3·2 to 6·6)
30·5% 
(26·8 to 34·8)
3·36% 
(2·19 to 4·43)
0·89% 
(–0·25 to 1·94)
1·09% 
(–0·05 to 2·14)
Somalia 15 
(13 to 17)
30 
(27 to 34)
15·6% 
(14·0 to 17·5)
20·0% 
(15·6 to 25·0)
28·7% 
(21·2 to 36·5)
49·8% 
(44·2 to 55·3)
3·63% 
(2·43 to 4·85)
1·00% 
(–0·16 to 2·19)
1·41% 
(0·25 to 2·61)
South Africa 512 
(460 to 564)
1162 
(1046 to 1282)
5·6% 
(5·1 to 6·2)
53·6% 
(48·5 to 58·8)
7·8% 
(5·7 to 10·0)
2·3% 
(2·1 to 2·6)
3·15% 
(2·33 to 3·90)
2·00% 
(1·18 to 2·74)
0·53% 
(–0·27 to 1·26)
South Korea 2150 
(2088 to 2217)
2833 
(2751 to 2922)
7·1% 
(6·9 to 7·3)
59·1% 
(57·6 to 60·4)
33·4% 
(32·0 to 34·8)
0·0% 
(0·0 to 0·0)
7·67% 
(7·28 to 8·09)
7·06% 
(6·67 to 7·48)
3·30% 
(2·92 to 3·70)
South Sudan 52 
(44 to 62)
248 
(208 to 293)
2·8% 
(2·4 to 3·3)
43·8% 
(35·2 to 52·3)
36·0% 
(26·9 to 46·2)
15·6% 
(13·1 to 18·5)
5·26% 
(3·85 to 6·66)
1·05% 
(–0·30 to 2·39)
0·53% 
(–0·81 to 1·86)
Spain 2687 
(2608 to 2766)
3419 
(3318 to 3519)
7·2% 
(7·0 to 7·4)
71·2% 
(69·8 to 72·5)
23·9% 
(22·7 to 25·1)
0·0% 
(0·0 to 0·0)
3·39% 
(3·12 to 3·64)
2·62% 
(2·35 to 2·88)
1·23% 
(0·96 to 1·48)
Sri Lanka 159 
(134 to 188)
505 
(427 to 596)
3·5% 
(3·0 to 4·2)
43·6% 
(35·7 to 51·3)
48·9% 
(41·0 to 57·3)
1·4% 
(1·2 to 1·7)
3·54% 
(2·31 to 4·75)
2·93% 
(1·70 to 4·13)
–1·61% 
(–2·79 to –0·46)
Sudan 113 
(93 to 136)
265 
(220 to 320)
5·1% 
(4·2 to 6·1)
23·2% 
(17·7 to 29·7)
69·2% 
(61·9 to 75·7)
3·9% 
(3·2 to 4·6)
5·25% 
(3·96 to 6·71)
2·70% 
(1·44 to 4·12)
0·04% 
(–1·19 to 1·42)
Suriname 417 
(372 to 466)
939 
(837 to 1047)
4·8% 
(4·3 to 5·4)
61·1% 
(55·1 to 66·6)
22·4% 
(18·1 to 27·2)
0·6% 
(0·6 to 0·7)
0·96% 
(0·20 to 1·71)
0·02% 
(–0·74 to 0·76)
–1·83% 
(–2·57 to –1·11)
Sweden 6095 
(5899 to 6299)
5757 
(5572 to 5950)
8·6% 
(8·3 to 8·8)
83·5% 
(82·5 to 84·3)
15·3% 
(14·5 to 16·1)
0·0% 
(0·0 to 0·0)
4·44% 
(4·08 to 4·79)
3·87% 
(3·50 to 4·21)
1·88% 
(1·52 to 2·21)
Switzerland 10 036 
(9841 to 10 235)
7601 
(7454 to 7752)
9·9% 
(9·7 to 10·1)
62·9% 
(62·0 to 63·7)
29·5% 
(28·7 to 30·2)
0·0% 
(0·0 to 0·0)
2·84% 
(2·68 to 3·01)
1·98% 
(1·82 to 2·16)
0·95% 
(0·78 to 1·12)
Syria 44 
(36 to 53)
773 
(631 to 934)
2·4% 
(2·0 to 2·9)
44·7% 
(35·1 to 53·8)
50·0% 
(40·6 to 59·9)
1·5% 
(1·3 to 1·9)
–2·10% 
(–3·30 to –0·81)
–3·18% 
(–4·37 to –1·91)
–1·90% 
(–3·11 to –0·62)
Taiwan (province of 
China)
1632 
(1538 to 1726)
3118 
(2938 to 3297)
6·4% 
(6·0 to 6·7)
59·6% 
(56·7 to 62·4)
36·9% 
(34·3 to 39·2)
0·0% 
(0·0 to 0·0)
5·31% 
(4·93 to 5·70)
4·76% 
(4·38 to 5·15)
1·14% 
(0·77 to 1·51)
Tajikistan 53 
(43 to 66)
210 
(169 to 261)
4·5% 
(3·6 to 5·6)
27·8% 
(20·7 to 35·2)
63·1% 
(54·9 to 71·3)
8·8% 
(7·0 to 10·8)
9·76% 
(8·29 to 11·41)
7·65% 
(6·20 to 9·26)
3·66% 
(2·27 to 5·21)
Tanzania 41 
(36 to 46)
129 
(116 to 147)
4·0% 
(3·6 to 4·6)
34·3% 
(27·9 to 40·8)
22·8% 
(16·8 to 30·0)
41·6% 
(36·5 to 46·3)
5·73% 
(4·45 to 6·98)
2·81% 
(1·56 to 4·01)
–0·41% 
(–1·61 to 0·76)
Thailand 231 
(200 to 265)
654 
(566 to 751)
3·2% 
(2·8 to 3·7)
77·3% 
(70·6 to 82·8)
12·3% 
(8·9 to 16·6)
0·3% 
(0·2 to 0·3)
3·80% 
(2·73 to 4·81)
3·22% 
(2·15 to 4·22)
0·70% 
(–0·34 to 1·68)
The Bahamas 1938 
(1865 to 2020)
1976 
(1901 to 2059)
6·6% 
(6·4 to 6·9)
49·9% 
(47·9 to 51·8)
27·7% 
(26·0 to 29·6)
0·0% 
(0·0 to 0·0)
2·64% 
(2·34 to 2·93)
0·95% 
(0·66 to 1·24)
0·99% 
(0·70 to 1·27)
The Gambia 29 
(26 to 31)
104 
(95 to 114)
4·8% 
(4·4 to 5·3)
16·2% 
(12·7 to 20·1)
18·2% 
(13·6 to 24·0)
56·9% 
(51·5 to 61·9)
5·24% 
(4·12 to 6·33)
2·11% 
(1·02 to 3·17)
1·75% 
(0·67 to 2·80)
(Table 1 continues on next page)
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Results
Overview 
This analysis focuses on the past, present, and future of 
global health financing. First, we present levels of health 
spending and trends in health spending for the 
historical period from 1995 to 2016, and the analysis of 
factors contributing to increases in government health 
spending. Second, we highlight the role that DAH has 
played in providing resources for health, especially to 
low-income countries from 1990 to 2018. Third, we 
focus on health spending in 2016, and assess varia-
tions in the composition of financing sources across 
countries. Fourth, we present future scenarios of 
health spending, assessing levels and growth rates of 
health spending from 2017 to 2050, with an additional 
emphasis on 2030, given its significance as the target 
Health spending 
per capita, 2016 
(US$)
Health spending 
per capita, 2016 
($PPP)
Health 
spending per 
GDP, 2016
Government 
health 
spending per 
total health 
spending, 
2016 
Out-of-pocket 
spending per 
total health 
spending, 
2016 
Development 
assistance for 
health per 
total health 
spending, 
2016 
Annualised rate 
of change in 
health spending, 
1995–2016 
(US$) 
Annualised rate 
of change in 
health spending 
per capita, 
1995–2016 
(US$) 
Annualised rate 
of change in 
health spending 
per GDP, 
1995–2016 
(US$)
(Continued from previous page)
Timor-Leste 85 
(73 to 101)
209 
(178 to 245)
2·0% 
(1·7 to 2·3)
65·2% 
(59·1 to 70·9)
10·6% 
(7·3 to 14·6)
22·9% 
(19·3 to 26·6)
6·79% 
(5·55 to 8·05)
5·07% 
(3·85 to 6·30)
1·21% 
(0·03 to 2·40)
Togo 41 
(34 to 50)
108 
(89 to 131)
5·6% 
(4·6 to 6·8)
21·9% 
(16·8 to 28·3)
54·8% 
(45·4 to 63·0)
14·6% 
(11·9 to 17·5)
5·06% 
(3·44 to 6·63)
2·31% 
(0·73 to 3·84)
2·05% 
(0·48 to 3·57)
Tonga 219 
(196 to 245)
322 
(287 to 360)
4·4% 
(3·9 to 4·9)
56·2% 
(50·9 to 61·2)
10·2% 
(7·2 to 13·4)
29·1% 
(25·9 to 32·6)
3·48% 
(2·56 to 4·40)
3·05% 
(2·13 to 3·96)
2·03% 
(1·12 to 2·93)
Trinidad and Tobago 1048 
(983 to 1111)
2148 
(2014 to 2278)
5·1% 
(4·8 to 5·4)
52·1% 
(49·4 to 55·0)
40·7% 
(38·0 to 43·3)
0·0% 
(0·0 to 0·0)
5·79% 
(5·13 to 6·42)
5·47% 
(4·81 to 6·09)
1·33% 
(0·69 to 1·93)
Tunisia 242 
(211 to 275)
847 
(738 to 963)
4·8% 
(4·2 to 5·5)
56·8% 
(49·5 to 63·7)
39·1% 
(32·1 to 46·0)
0·7% 
(0·6 to 0·8)
5·28% 
(4·22 to 6·29)
4·27% 
(3·22 to 5·27)
1·53% 
(0·51 to 2·50)
Turkey 445 
(405 to 490)
1107 
(1009 to 1220)
2·9% 
(2·6 to 3·2)
77·9% 
(73·4 to 82·1)
16·8% 
(13·2 to 20·8)
0·1% 
(0·1 to 0·1)
6·67% 
(5·84 to 7·46)
5·17% 
(4·35 to 5·94)
1·87% 
(1·08 to 2·63)
Turkmenistan 511 
(462 to 565)
1382 
(1249 to 1528)
5·8% 
(5·2 to 6·4)
21·2% 
(17·5 to 25·0)
73·6% 
(69·2 to 77·7)
0·4% 
(0·3 to 0·4)
7·02% 
(6·05 to 7·94)
5·63% 
(4·67 to 6·54)
–1·00% 
(–1·90 to –0·15)
Uganda 44 
(38 to 50)
153 
(134 to 177)
6·0% 
(5·2 to 6·9)
16·0% 
(12·2 to 20·2)
38·2% 
(30·1 to 46·3)
43·0% 
(37·1 to 49·0)
5·66% 
(4·44 to 6·85)
2·29% 
(1·11 to 3·43)
–0·68% 
(–1·83 to 0·43)
Ukraine 171 
(146 to 197)
567 
(485 to 654)
4·7% 
(4·0 to 5·4)
43·3% 
(36·3 to 50·6)
52·3% 
(44·8 to 59·5)
1·3% 
(1·1 to 1·5)
1·28% 
(0·20 to 2·31)
1·81% 
(0·73 to 2·85)
0·10% 
(–0·96 to 1·12)
United Arab 
Emirates
1440 
(1346 to 1538)
2586 
(2417 to 2762)
2·8% 
(2·6 to 3·0)
72·1% 
(68·6 to 75·3)
18·1% 
(15·5 to 20·9)
0·0% 
(0·0 to 0·0)
6·43% 
(5·97 to 6·91)
–0·29% 
(–0·72 to 0·16)
1·68% 
(1·24 to 2·14)
UK 4113 
(4010 to 4216)
4364 
(4254 to 4473)
8·3% 
(8·0 to 8·5)
80·0% 
(78·7 to 81·2)
15·3% 
(14·3 to 16·5)
0·0% 
(0·0 to 0·0)
4·97% 
(4·68 to 5·24)
4·37% 
(4·08 to 4·64)
2·82% 
(2·54 to 3·09)
Uruguay 1520 
(1457 to 1586)
2049 
(1965 to 2138)
8·6% 
(8·2 to 8·9)
71·2% 
(68·8 to 73·4)
17·2% 
(15·5 to 18·8)
0·0% 
(0·0 to 0·0)
2·44% 
(2·07 to 2·85)
2·10% 
(1·73 to 2·51)
–0·45% 
(–0·82 to –0·06)
USA 10 271 
(10 054 to 10 498)
10 271 
(10 054 to 10 498)
17·1% 
(16·8 to 17·5)
81·8% 
(81·2 to 82·5)
11·1% 
(10·6 to 11·5)
0·0% 
(0·0 to 0·0)
4·03% 
(3·84 to 4·23)
3·08% 
(2·89 to 3·28)
1·61% 
(1·42 to 1·80)
Uzbekistan 76 
(63 to 93)
423 
(348 to 513)
3·2% 
(2·6 to 3·9)
47·3% 
(37·6 to 56·7)
48·4% 
(39·1 to 58·4)
3·9% 
(3·2 to 4·7)
5·71% 
(4·39 to 7·13)
4·26% 
(2·96 to 5·66)
–0·53% 
(–1·78 to 0·80)
Vanuatu 96 
(83 to 112)
84 
(73 to 98)
2·7% 
(2·3 to 3·1)
60·3% 
(53·7 to 66·3)
10·4% 
(7·3 to 14·4)
25·0% 
(21·4 to 28·8)
3·06% 
(1·80 to 4·24)
0·80% 
(–0·44 to 1·94)
0·41% 
(–0·82 to 1·55)
Venezuela 384 
(345 to 427)
636 
(572 to 708)
4·1% 
(3·7 to 4·6)
33·2% 
(28·4 to 38·3)
33·8% 
(29·0 to 38·9)
0·0% 
(0·0 to 0·0)
–0·28% 
(–0·98 to 0·42)
–1·96% 
(–2·64 to –1·27)
–1·14% 
(–1·84 to –0·45)
Vietnam 119 
(98 to 140)
347 
(287 to 409)
5·5% 
(4·6 to 6·5)
49·6% 
(41·1 to 58·4)
46·7% 
(38·0 to 55·5)
2·7% 
(2·3 to 3·3)
7·97% 
(6·62 to 9·29)
6·71% 
(5·37 to 8·01)
1·27% 
(0·00 to 2·50)
Virgin Islands 2196 
(1799 to 2665)
1180 
(967 to 1432)
6·3% 
(5·1 to 7·6)
63·4% 
(53·6 to 72·5)
26·1% 
(18·6 to 34·9)
0·0% 
(0·0 to 0·0)
4·27% 
(2·82 to 5·71)
4·31% 
(2·86 to 5·75)
2·92% 
(1·49 to 4·34)
Yemen 59 
(47 to 73)
126 
(100 to 157)
9·2% 
(7·3 to 11·5)
14·1% 
(10·2 to 18·9)
79·8% 
(74·0 to 84·7)
5·2% 
(4·1 to 6·4)
1·96% 
(0·62 to 3·47)
–1·08% 
(–2·38 to 0·38)
2·42% 
(1·08 to 3·93)
Zambia 64 
(57 to 72)
187 
(167 to 209)
3·2% 
(2·9 to 3·6)
38·1% 
(31·6 to 45·0)
12·3% 
(8·7 to 16·4)
44·0% 
(39·2 to 49·1)
3·85% 
(2·76 to 4·82)
0·98% 
(–0·07 to 1·93)
–1·81% 
(–2·84 to –0·89)
Zimbabwe 106 
(91 to 124)
198 
(171 to 231)
9·7% 
(8·3 to 11·3)
45·0% 
(37·8 to 52·8)
26·5% 
(19·9 to 33·5)
18·9% 
(16·1 to 21·8)
1·89% 
(0·60 to 3·12)
0·36% 
(–0·92 to 1·56)
0·95% 
(–0·34 to 2·16)
Estimates in parentheses are 95% uncertainty intervals. PPP=2018 purchasing-power parity-adjusted dollars. GDP=Gross domestic product. GBD=Global Burden of Disease. 
Table 1: Health spending by source, 2016
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year for achieving the Sustainable Development Goals. 
Finally, we highlight observed and expected trends 
during the entire study period. All estimates made in 
this Article are available to view in an associated 
visualisation, available on Viz Hub.
Past and present
In 1995, health spending globally was $3·5 trillion 
(95% uncertainty interval [UI] 3·4–3·5), $4·3 trillion 
(4·2–4·4) in purchasing-power parity-adjusted dollars, 
and comprised 6·9% (6·8–7·0) of global GDP. That 
year, 87·6% (87·1–88·1) was spent in countries that 
are currently high-income, 9·8% (9·4–10·3) in upper-
middle-income countries, 2·2% (2·1–2·4) in lower-
middle-income countries, and only 0·3% (0·3–0·4) in 
low-income countries. Health spending per capita 
globally was $612 (603–622), ranging from $5 (4–7) in 
Myanmar to $7318 (5490–10 192) in Bermuda (figure 1A). 
In 1995, countries currently classified as high income 
spent $2871 (2823–2921) per capita on health, whereas 
those classified as upper-middle income spent $158 
(150–166) per capita, those classified as lower-middle 
income spent $38 (35–41) per capita, and those classified 
as low income spent $30 (28–31) per capita. Health 
spending per capita was the lowest in South Asia, at 
$26 (21–31) per capita, and in sub-Saharan Africa, at 
$58 (54–62) per capita, and highest in GBD high-income 
countries, at $3206 (3151–3264) per capita.
Between 1995 and 2016, there was substantive growth in 
health spending in many countries, with a global growth 
rate of 4·00% (95% UI 3·89–4·12) annually, although 
this rate was lower for health spending per capita 
(2·72% [2·61–2·84]; figure 1B, figure 2, table 1). Countries 
with the largest absolute increases in annual per capita 
health spending during this period were the USA 
($4843 [4580–5125] increase), Norway ($3913 [3501–4327] 
increase), and Bermuda ($3485 [535–5916] increase), 
while spending increased by less than $1 per capita in 
22 countries. The most populous of these 22 countries 
are Venezuela, Yemen, and Angola. Figure 3 shows that 
the highest annual growth rates in per capita health 
spending were observed in upper-middle-income (5·55% 
[5·18–5·95]) and lower-middle-income countries (3·71% 
[3·10–4·34]). In upper-middle-income countries, the 
largest source of this increase was increased govern-
ment health spending (6·85% [6·37–7·34]) and in lower-
middle-income countries the fastest growth was in DAH 
(4·34%). These groups of countries also saw rapid annual 
growth in out-of-pocket spending: 3·54% (2·57–4·54) in 
lower-middle-income countries and 4·60% (4·01–5·22) 
in upper-middle-income countries. Although DAH per 
capita increased rapidly, at 6·74% annually in low-income 
countries, overall growth in health spending per capita 
remained low at 1·46% (1·13–1·80) per year in these 
countries. Geographically, southeast Asia, east Asia, and 
Oceania had the highest growth in health spending per 
Figure 3: Annualised rate of change in health spending per capita by source, by World Bank income group (A) and GBD super-region (B), 1995–2016
Error bars represent 95% uncertainty intervals. This figure was remade but with health spending measured as a percentage of gross domestic product, and is included in the appendix. GBD=Global 
Burden of Disease.
–5 0 5 10
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For more on the visualisation 
see https://vizhub.healthdata.
org/fgh/
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capita (8·52% [7·69 to 9·33]) annually between 1995 and 
2016, driven mainly by large growth in government health 
spending (10·76% [9·94 to 11·57]) and out-of-pocket 
spending (7·34% [6·15 to 8·59]), whereas sub-Saharan 
Africa had the lowest growth in health spending per capita 
(1·54% [1·08 to 1·97]), with only modest increases in 
government health spending (2·00% [1·45 to 2·53]) and 
out-of-pocket spending (0·65% [–0·12 to 1·44]). The 
negative growth (–3·49% [–3·75 to –3·22]) in prepaid 
private spending per capita in high-income countries 
(figure 3) is attributable to the enactment in 2014 of the 
insurance mandate in the US Affordable Care Act, which 
reclassified a large proportion of health spending that was 
originally prepaid private spending as government health 
spending because this spending became compulsory.13
Governments play an important role in the changing 
landscape of health financing and are globally the largest 
source of funds for health. Figure 4 highlights the amount 
of change in government health spending per capita 
between 1995 and 2016 that is associated with each of 
three key factors. Globally, the primary factor driving 
increases in government health spending was greater 
prioritisation of the health sector, which was associated 
with an increase of $299 (95% UI 287–311) in annual 
government spending on health per capita between 
1995 and 2016. The other key factor driving growth in 
government health spending per capita globally was 
economic development, associated with a $185 (165–207) 
increase per capita. Across regions and income groups, 
government prioritisation of health was the leading factor 
of change in high-income countries and in North Africa 
and the Middle East, whereas economic development was 
the key factor in upper-middle-income, lower-middle-
income, and low-income countries; in central Europe, 
eastern Europe, and central Asia; in south Asia; in 
southeast Asia, east Asia, and Oceania; and in sub-Saharan 
Africa. Increases in total government spending also led to 
substantial increases in government health spending in 
upper-middle-income countries, particularly in southeast 
Asia, east Asia, and Oceania and in Latin America and the 
Caribbean. The smallest increase in government health 
spending per capita was in low-income countries, 
especially in south Asia and sub-Saharan Africa; in these 
regions, economic development was the leading factor 
contributing to this growth.
Globally, health spending reached $8·0 trillion 
(95% UI 7·8–8·1) in 2016, $10·3 trillion (10·1–10·6) in 
purchasing-power parity-adjusted dollars, and comprised 
8·6% (8·4–8·7) of global GDP in 2016. 81·0% (80·0–81·9) 
was spent in high-income countries, 15·7% (14·9–16·6) 
in upper-middle-income countries, 3·0% (2·7–3·3) in 
lower-middle-income countries, and 0·4% (0·3–0·4) in 
low-income countries, despite low-income countries com-
prising 10·0% of the global population. 41·7% (40·9–42·5) 
of total health spending worldwide was in the USA alone, 
while the countries of sub-Saharan Africa collectively 
comprised 1·0% (0·9–1·0) of total health  spending. 
Health spending per capita increased to $1077 (1058–1096), 
despite significant variation across regions and income 
groups (figure 1B, table 1). Per capita health spending in 
high-income countries was $5252 (5184–5319), ranging 
from $261 (208–326) in the Northern Mariana Islands to 
$10 802 (9469–12 352) in Bermuda; and $40 (38–43) in 
low-income countries, ranging from $15 (13–17) in 
Somalia to $106 (91–124) in Zimbabwe. Disparities 
persist across geographical regions, with per capita 
spending ranging from $37 (29–48) in Bangladesh to 
$84 (69–100) in Bhutan in south Asia, where health 
spending is the lowest of all regions (table 1).
Figure 2 and figure 5A collectively highlight the 
hypotheses made in the health financing transition.31 
Figure 2 shows that the exponential relationship between 
GDP and health spending has persisted from 1995 to 2016. 
Figure 5A explores how the sources of health spending 
tend to evolve with economic development (similar figures 
showing this relationship in past and future years are 
provided in the appendix). Countries at a lower income 
level tend to have a higher proportion of out-of-pocket 
spending and DAH to finance the health sector; as 
countries get wealthier, less of their health spending is 
financed by DAH. As the proportion of health spending 
Figure 4: Factors of change in government health spending per capita, 1995–2016
Change in government health spending per capita by global (A), high-income (B), and low-income and 
middle-income countries (C), reported in inflation-adjusted 2018 US dollars. Error bars represent uncertainty 
intervals. Black dots represent the estimated change in government spending per capita. GBD=Global Burden of 
Diseases, Injuries, and Risk Factors. GDP=gross domestic product.
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Change in government health spending per capita, 1995-2016 (US$)
0 500 1000 1500 2000 2500
0 50 100 150 200 250 300 350 400 450 500 550
Global
World Bank high income
GBD high income
Sub-Saharan Africa
Southeast Asia, east Asia,
and Oceania
South Asia
North Africa and Middle East
Latin America and Caribbean
Central Europe, eastern Europe,
and central Asia
Low income
Lower-middle income
Upper-middle income
A Global
B GBD and World Bank high-income countries
C Low and middle-income countries 
(World Bank income groups and GBD super-regions)
Contributing factors GDP per capita Government spending Government prioritisation of health
Articles
2250 www.thelancet.com   Vol 393   June 1, 2019
that is DAH subsides, countries tend to fill the gap by 
further increasing out-of-pocket and government health 
spending, with an increasing proportion from gov ernment 
health spending as eco nomic development increases. This 
trend is seen by comparing the proportion of total spending 
from out-of-pocket spending in low-income and lower-
middle-income countries: in 2016, lower-middle-income 
countries had the highest share of spending from out-of-
pocket spending (56·1% [95% UI 47·3–65·4]), even higher 
than that of low-income countries (42·4% [38·3–47·0]), 
because low-income countries also had a large share of 
spending from DAH (25·4% [23·9–26·8]; table 1). Despite 
this global pattern, figure 5B and table 1 highlight the wide 
variation in the proportion of health spending that came 
from the government: 79·6% (78·2–81·1) of all spending 
in high-income countries in 2016 came from government 
health spending, as did 53·9% (49·9–58·6) in upper-
middle-income countries, 32·1% (28·4–36·1) in lower-
middle-income countries, and 26·3% (23·3–29·5) in 
low-income countries. Wide variation exists even for 
countries at similar levels of GDP per capita. In 2016, 
among low-income countries the proportion of health 
spending from the government ranged from 5·7% (3·9–
7·9) in Afghanistan to 61·9% (51·7–72·2) in North Korea; 
among lower-middle-income countries it ranged from 
14·5% (10·6–19·2) in Nigeria to 84·1% (79·9–87·5) in the 
Federated States of Micronesia; among upper-middle-
income countries it ranged from 15·8% (12·5–19·7) in 
Armenia to 90·1% (86·5–93·0) in American Samoa; and 
among high-income countries it ranged from 29·1% 
(25·1–33·0) in Bermuda to 100·0% (100·0–100·0) in 
Greenland (table 1).
Development assistance for health
Although government health spending did not grow 
substantially in countries that are currently classified 
as low-income, DAH had the fastest growth in health 
spending per capita in these countries (figure 3). 
Figure 6 (A–C) shows that in 1990, total DAH disbursed to 
low-income and middle-income countries was $7·7 billion. 
Between 1990 and 2000, DAH increased at 5·69% annu-
ally, whereas between 2000 and 2010 it increased at 
10·03% annually. More recently, DAH disbursement has 
levelled, with annual growth from 2010 through 2018 
estimated to be 1·33%.
In 2018, total DAH reached $38·9 billion, with the USA 
as the largest single source of contributions in terms of 
volume, providing $13·2 billion (33·8% of total DAH); 
the UK as the second largest single contributing source, 
providing $3·3 billion (8·4%); and the Bill & Melinda 
Gates Foundation as the third largest single contributing 
source, providing $3·2 billion (8·3%; figure 6A). Despite 
having a lower income per capita than all other national 
contributors, China provided $644·7 million of DAH in 
2018. Figure 6B shows the annual total DAH by disbursing 
agency. The largest multilateral and public–private partner-
ships that disbursed DAH in 2018 included the Global 
Fund ($3·2 billion; 8·2% of the total disbursed), WHO 
($2·6 billion, 6·6%), and UNICEF ($1·9 billion, 4·9%). 
The Coalition for Epidemic Preparedness Innovation 
disbursed $71·0 million.
Figure 6C highlights the annual total DAH targeted to 
different health focus areas over time. Although all 
health focus areas tracked in this study have more DAH 
targeting them now than in 1990, this growth has 
Figure 5: Economic development and the composition of health spending by source and proportion of health 
spending from the government in 2016
Composition by source (A) and proportion of health spending from the government (B). Each dot represents a 
country colour-coded by World Bank income group. Gross domestic product per capita reported in 
inflation-adjusted 2018 US dollars. The x-axes are presented in natural logarithmic scale.
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been especially acute for funding allocated to HIV/AIDS, 
malaria, and tuberculosis, all of which increased at more 
than 20% per year between 2000 and 2010 (figure 6D). 
More recently, DAH targeting newborn and child 
health and infectious diseases other than HIV/AIDS, 
malaria, and tuberculosis grew most quickly, growing at 
6·19% and 6·27% annually between 2010 and 2018. 
During this same period, DAH for HIV/AIDS reduced, 
with an annualised decline of 2·05% per year between 
2010 and 2018, or a reduction of $1·7 billion since the 
2012 peak. Still, in 2018, HIV/AIDS received more DAH 
than any other health focus area ($9·5 billion [24·3% of 
the total]). Newborn and child health received the second 
most DAH ($7·8 billion [20·1%]), sector-wide approaches 
and health sector support received the third most DAH 
($5·6 billion [14·3%]), and reproductive and maternal 
health received the fourth most DAH in 2018 ($4·7 billion 
[12·1%]). In 2018, we estimated that $48·3 million of 
DAH targeted antimicrobial resistance.
Future
Sustained growth in health spending is expected to 
continue, with global spending projected to reach 
$10·6 tril lion (95% UI 10·2–10·9) in 2030 and 
$15·0 trillion (14·0–16·0) in 2050 (table 2, figure 1C, 1D). 
In purchasing-power parity-adjusted dollars, these values 
are $14·3 trillion (13·7–15·0) in 2030 and $21·3 trillion 
(19·8–23·1) in 2050. These values are projected to 
comprise 8·9% (8·4–9·4) of global GDP in 2030 and 
9·4% (7·6–11·3) of global GDP in 2050. Despite this 
Figure 6: Changes in development assistance for health disbursements, 1990–2018
Development assistance for health by source of funding (A), channel of assistance (B), health focus area (C), and annualised rate of change by health focus area (D). Reported in billions of 
inflation-adjusted 2018 US dollars. World Bank includes the International Development Association and the International Bank for Reconstruction and Development (IBRD); and regional 
development banks include the Inter-American Development Bank, the African Development Bank, and the Asian Development Bank. CEPI=Coalition for Epidemic Preparedness Innovations. 
Gates Foundation=Bill & Melinda Gates Foundation. Gavi=Gavi, the Vaccine Alliance. NGOs=non-governmental organisations. PAHO=Pan American Health Organization. *Data for 2018 are 
preliminary estimates based on budget data and estimation.
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growth, health spending is expected to remain skewed, 
with 69·4% (67·2–71·5) of this spending in countries 
that are currently considered high-income, 
25·1% (23·1–27·1) in upper-middle-income countries, 
4·9% (4·4–5·5) in lower-middle-income countries, and 
only 0·6% (0·6–0·7) in low-income countries, despite 
low-income countries comprising an estimated 15·7% 
of the global population by 2050. In per-capita terms, 
projected total health spending globally is $1264 
(1219–1309) per capita in 2030 and $1667 (1567–1767) per 
capita in 2050 (table 2). Per capita spending in 2030 is 
projected to be $6313 (6135–6499) for high-income 
groups, $772 (707–847) for upper-middle-income groups, 
$121 (108–137) for lower-middle-income groups, and $48 
(44–51) for low-income groups. In 2050, this spending is 
projected to increase to $8286 (7851–8725) for high-
income groups, $1435 (1264–1632) for upper-middle-
income groups, $200 (176–225) for lower-middle-income 
groups, and $66 (60–73) for low-income groups (table 2). 
The fastest growth in per capita health spending is 
predicted among lower-middle-income countries, with 
2·64% (2·28–3·02) annual growth per capita projected 
between 2017 and 2050, and upper-middle-income 
countries, with 3·20% (2·84–3·58) annual growth per 
capita projected between 2017 and 2050 (table 2). Health 
spending per capita in 2050 is expected to remain the 
lowest in sub-Saharan Africa ($111 [102–121]) and South 
Asia ($180 [146–220]).
The two regions with the lowest projected growth rate 
in total health spending between 2017 and 2050 are the 
GBD high-income region, with a growth rate of 1·38% 
(95% UI 1·22–1·54), and central Europe, eastern Europe, 
and central Asia, with a growth rate of 1·44% (1·25–1·63; 
table 2). Despite this similarity, the growth rates in health 
spending per capita are actually quite distinct (1·31% 
[1·15–1·47] for the GBD high-income region and 1·76% 
[1·57–1·95] for central Europe, eastern Europe, and central 
Asia), because of differences in population growth. 
Population projections have a large impact on health 
spending per capita growth rates (table 2); unlike central 
Europe, eastern Europe, and central Asia, where population 
growth is lower than zero, meaning the population growth 
is well below replacement, population growth is expected 
to remain high in North Africa and the Middle East, and 
especially in sub-Saharan Africa. In this region, annualised 
health spending growth between 2017 and 2050 is expected 
to be 3·07% (2·82–3·32), although health spending per 
capita growth is expected to be 0·97% (0·73–1·19; table 2).
Our future scenarios of government health spending 
(figure 7) estimate the potential additional funding 
governments might be able to mobilise if the health 
sector is further prioritised or if governments increase 
spending overall, or if both are achieved. In scenario 1, in 
2050, increased prioritisation of health by governments 
could lead to an additional $229 (95% UI 212–267) in 
health spending per capita, compared to the reference 
scenario. In scenario 2, in 2050, increased prioritisation 
of health and increased total government spending could 
lead to an additional $617 (605–660) per person. In both 
scenarios, the potential increase in government health 
spending per capita is more than double the projection 
in the reference scenario in some countries. Furthermore, 
these potential gains are proportionally greater in low-
income and lower-middle-income countries and south 
Asia and sub-Saharan Africa, relative to the low levels of 
government health spending in the reference scenario 
(table 2).
Past to the present to the future
Examining the full set of results spanning 1995 to 2050, 
we observe three persistent trends. The first trend is an 
ongoing increase in health spending over time, as shown 
by the upward push in the curves in figure 2. Countries 
at the same level of income as other countries in the past 
tend to spend more on health than those other countries 
did, especially countries with higher levels of economic 
development. The second trend, seen across most 
regions and income groups, is of positive, albeit slowing, 
growth rates in health spending, as well as declining 
population growth rates. Because population growth was 
generally dropping at the same rate as health spending, 
or at a faster rate, health spending per capita growth 
appears to be flattening or increasing. Sub-Saharan 
Africa stands out in particular, as population growth is 
noticeably higher than elsewhere in the early 2000s, but 
is decreasing over time, leading to a slow increase in 
health spending per capita growth rate. The third trend is 
increasing disparities in total and government health 
spending, even among countries in the same income 
group. As shown in figure 2, despite the fact that the 
majority of countries are moving upwards over time to 
higher total health spending per capita, the gap between 
the smallest and the largest health spenders per capita 
has grown from $7313 (95% UI 6453–10 185) per capita in 
1995, to $10 787 (9456–12 335) per capita in 2016, to a 
projected value of $15 806 (14 654–16 913) in 2050. 
Between income groups, in 1995, per capita health 
spending in high-income countries was 96·4 times 
(91·3–101·6) greater than the spending in low-income 
countries; this ratio increased to 130·2 (122·9–136·9) in 
2016 and is projected to stay at similar levels in the future, 
at 133·0 (123·7–142·4) in 2030 and 125·9 (113·7–138·1) 
in 2050. Figure 7 shows the changes in the distribution of 
government health spending per capita by income group 
over time. Although there is clear overall shifting of 
distributions towards the upper end during the study 
period, accompanying this trend are the countries that 
are left behind from this positive shift and the large 
discrepancy in values between high-income and low-
income countries, which are shown on different scales. 
Especially in low-income and middle-income groups, the 
gap between countries with the highest and lowest 
government health spending per capita is projected to 
widen between now and the future.
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Discussion
Overview 
Globally, health spending has risen steadily since 1995, 
reaching $8·0 trillion (95% UI 7·8–8·1) in 2016 and 
projected to further increase to a total of $15·0 trillion 
(14·0–16·0) by 2050, but at a slower rate of growth in 
the majority of countries. Health spending currently 
constitutes 8·6% (8·4–8·7) of the global economy, with 
the largest proportions of this spending financed by 
governments and spent in high-income countries. 
Sub-Saharan Africa and low-income countries currently 
have the lowest levels of spending, with 1·0% (0·9–1·0) 
of the global total in sub-Saharan Africa and 0·4% 
(0·3–0·4) of the global total in low-income countries. 
The composition of health spending by financing source 
has changed and will continue to evolve in the future. In 
2016, increased proportions of global health spending 
came from government (74·0% [72·5–75·5]) and DAH 
(0·2% [0·2–0·2]), and decreased proportions from out-
of-pocket spending (18·6% [18·0–19·4]). However, DAH 
has plateaued since 2010, leading to a renewed emphasis 
on domestic resource mobilisation in recent years. By 
2050, we project a problematic shift in this trend, 
with government health spending declining to 72·9% 
(68·4–77·5), and slight increases in out-of-pocket 
spending (19·0% [17·4 to 20·8]).
Sustaining growth in government health spending is 
important because this spending can provide funding 
for essential health services.32 Furthermore, increased 
government health spending can indirectly affect health 
outcomes by increasing household financial resources for 
other health determinants, such as food and education, as 
a result of reduced spending on health care.33 Given that 
government spending is a source of pooled spending, it 
could also help spread the risk of financial burden caused 
by health care across the population. This pooling is 
Figure 7: Distribution of government health spending per capita, globally and by income group, for 1995, 2016, 2030, 2050, and two future scenarios
Reported in inflation-adjusted 2018 US dollars. 2050 scenario 1 reflects the increase in government health spending if all countries met the target proportion of 
government spending on health. 2050 scenario 2 reflects the increase in government health spending if all countries met the target proportion of government 
spending on health and target proportion of gross domestic product that is based on government spending. The x-axes are presented in a natural logarithmic scale. 
This figure was remade with health spending measured as a percentage of gross domestic product, and is included in the appendix.
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particularly important given the finding that out-of-pocket 
spending is projected to increase in many low-income and 
middle-income countries. Financial protection is a core 
tenet of universal health coverage and these projections 
suggest that many countries are not on track to adequately 
cover their populations.
Our future government health spending scenarios 
suggest that, with greater prioritisation of the health 
sector or increased total government spending, a drastic 
increase in government health spending per capita could 
be achieved, especially in countries currently with low 
levels of government health spending. The two scenarios 
assessed how much fiscal space there is and opportunities 
for expansion, although without considering other 
demands (eg, debt) on government spending. This is 
consistent with findings from recent work by WHO, 
which concluded that low-income countries have been 
lagging in the growth of government health spending.34 
The low ratio of tax revenue to GDP in many low-income 
countries exemplifies this challenge.35 Furthermore, 
work by the Organisation for Economic Co-operation 
and Development (OECD) points to the difficulty of 
sustaining current patterns of health financing from 
public sources in the future.
Patterns of past and projected health spending are 
useful for characterising countries’ progress along the 
health financing transition.31 This can be described as a 
rise in per capita health spending with a declining 
proportion from out-of-pocket and donor assistance. This 
is exemplified by the proportion of health spending that 
was out of pocket in 2016, which peaked among lower-
middle-income countries (56·1% [47·3–65·4]). The term 
“missing middle” has been used to characterise the 
problematic situation for countries at a middle level of 
income—as they begin to receive less DAH but do not yet 
fill the gap in financing with government spending, and 
instead rely more on additional out-of-pocket spending.36 
In figure 5A, which shows this relationship cross-
sectionally in 2016, the “missing middle” phenomenon 
appears to peak for lower-middle-income countries. Key 
strategies to help prevent countries from falling into this 
circumstance include sustaining DAH as countries reach 
middle-income status or development of robust domestic 
health financing systems early in a country’s economic 
development.
These results have important implications for policy, 
both at national and international levels. For countries 
and regions projected to have the slowest increases in 
government and prepaid private spending, domestic 
health financing reforms that increase levels of prepaid 
resources should be a priority as these populations risk 
falling further behind in the global push toward universal 
health coverage and in reducing child and adult mortality. 
Likewise, donors should consider these financing 
trajectories when making allocation decisions, possibly 
prioritising countries expected to have the slowest growth 
in domestic pooled spending. The projected persistence 
of severe global disparities in health spending requires 
the global community to consider and develop domestic 
and international policies that address the causes and 
effects of these inequities. High-income countries spent 
130·2 times (95% UI 122·9–136·9) more on health per 
capita than low-income countries in 2016, and this trend 
is expected to continue into the future. The strong 
relationship between GDP and health spending suggests 
that supporting economic development in the poorest 
countries is an important approach for improving equity 
in health financing across countries. There are many 
examples of countries that have substantially increased 
health spending as their economies have grown. Still, 
there are other important cases where countries have 
increased health spending much faster than their 
economic growth. These countries, such as China, 
South Korea, and Cuba, highlight what is possible with 
political will and investments in health.
Although the beginning of the 21st century coincided 
with a period of substantial increase in resources dedicated 
towards global health goals, growth in overall DAH has 
plateaued more recently. For some health focus areas, 
such as HIV/AIDS and health-systems strengthening, 
which have the potential to promote sustainable health 
systems in recipient countries, funding has reduced. Also 
of note is the relatively small share of DAH currently 
targeted at non-communicable diseases, despite these 
diseases accounting for the majority of the global disease 
burden.37 Even so, contributions from emerging donors 
such as China have the potential to provide new financing 
streams. Increasingly, China has become an important 
stakeholder in global health, including contributing 
substantially to the Ebola containment efforts in 2014 and 
to the establishment of the Africa Center for Diseases and 
Control thereafter.38,39 Globally, other innovative financing 
mechanisms for pooling additional resources to leverage 
development assistance efforts have been established. For 
example, the Global Financing Facility was established in 
2015 as a catalyst to align financing from international 
partners, the private sector, and country governments 
around country-owned investment cases related to 
reproductive, maternal, and child health.
As health spending growth rates decline or sources of 
funding plateau, it is especially important to understand 
the factors that improve the efficiency of health spending. 
It is important to note that increases in health spending do 
not necessarily translate into improvements in access to 
care, quality of care, or health outcomes. Additional 
research is needed to identify policies, such as strength-
ening supply chains, and attributes of health systems and 
governments, such as reduced corruption, that lead to 
more efficient spending and improvements in intermediate 
outputs and outcomes of health systems. Understanding 
and implementing effective political and policy changes 
that support more efficient use of financial resources for 
health will help countries to better utilise limited resources 
to work toward universal health coverage and improved 
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population health. Furthermore, whether increasing 
health spending should be viewed positively or negatively 
(and therefore promoted or curbed) should be determined 
according to the broader context. While additional health 
spending in countries with very low health spending is 
essential to meeting important global health goals, some 
high-income countries are concerned about the continuous 
growth in health spending and are searching for policies to 
curb these trends.
Limitations
This study has some limitations. First, although we used 
estimation methods that account for challenges related to 
the reliability and completeness of publicly available 
historical global health spending data, we acknowledge 
that the input data had some weaknesses. For certain 
countries the extracted data were not tied to an underlying 
data source or they did not seem to have credible year-
over-year trends. In these cases, we modelled domestic 
spending ourselves rather than relying on observed 
data. Additionally, we used the definition of spending 
used by the System of Health Accounts and the WHO 
GHED, which excludes investment spending, informal 
payments, and all spending that falls outside of the health 
system, including cross-sectoral investments. Population 
estimates used to compute per capita values are subject to 
similar data limitations, and this is especially true for 
countries with civil unrest and large migration patterns. 
Second, uncertainty intervals provided throughout this 
Article reflect uncertainty in both the retrospective and 
prospective data. The widening of uncertainty intervals as 
we push further into the future reflects the challenges in 
using trends and relationships from a short time span in 
the past to project into the future as well as incorporating 
unexpected future events and changes. Third, the out-of-
sample predictive validity of our models was tested on the 
past 10 years of observed data. This process determined 
the models picked for projecting growth rates. Therefore, 
our future scenarios are dependent on any observed 
shocks in the recent past, which would be difficult to 
predict out of sample. Similarly, projections are based on 
past trends and relationships, and our models cannot 
anticipate events, such as natural disasters or other 
unexpected events, that have never occurred. Fourth, our 
projections of available DAH rely primarily on growth 
in GDP, but we acknowledge that other political and 
commercial factors also drive the allocation of DAH from 
donors to recipient countries. Fifth, we were not able to 
measure health spending inequities within countries 
(eg, those across subnational regions, income levels, 
ethnic groups, and so on). Although some countries are 
projected to have large gains in health spending during 
the study period, the benefits are not likely to be 
distributed equally across subgroups. Country-specific 
contexts and determinants of health spending, such as 
domestic policies and political movements, are not 
discussed here but are important when designing 
country-specific policies. Finally, our prediction models 
do not capture the dynamic nature of health spending, in 
that health spending leads to better health, which can also 
lead to economic growth.
The data going into our modelling were all prepared in 
US dollars. US dollars were seen to be more stable across 
countries and observed years than purchasing-power 
parity-adjusted dollars, and more comparable to existing 
studies. Each currency has strengths, but neither 
US dollars nor purchasing-power parity-adjusted dollars 
are a perfect measure. US dollars value spending most 
accurately for tradable goods, but purchasing-power 
parity-adjusted estimates provide a better reflection of 
domestic spending on non-tradeable goods and are better 
for cross-country comparisons. Although neither of the 
currencies is measured perfectly in the data, having a 
more stable input to our models allowed us to produce 
more reliable estimates.
Conclusions
Health spending per capita, which has increased steadily 
since 1995, is projected to continue increasing well into 
the future, but at a slower rate of growth, and large 
existing disparities in per capita spending by country are 
projected to persist in the coming decades. Increasing 
prioritisation of health and total government spending 
are key factors to facilitate the health financing transition 
in all countries, whereby additional domestic resources 
are mobilised for health to gradually replace high out-of-
pocket payments. Sustained increases in the quantity, 
equity, and efficiency of health financing are essential 
to achieving universal health coverage and improving 
health outcomes globally.
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